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Chapter 1
Introducti on and outline of the thesis
10 | Chapter 1
The most common benign tumor of the cerebelloponti ne angle is variously known as 
acousti c neurinoma, acousti c neuroma or acousti c schwannoma and accounts for 6% 
to 8% of all intracranial neoplasms. The nomenclature of the tumor, however, changes 
over ti me. Because the tumor most commonly arises from the superior vesti bular 
nerve instead of the acousti c division of the eight cranial nerve and is composed 
of the Schwann cells in the neurilemma, the more adequate term “vesti bular 
schwannoma” (VS) has been proposed and will therefore be used throughout this 
thesis (1,2). 
The incidence rate of VS now varies between 1-1.5 per 100,000/ year, although the 
widespread use of magneti c resonance imaging (MRI) may lead to detecti on of more 
tumors and an increase of the incidence rate (3-5). VS are usually found in adults with 
a mean age ranging from 46 to 58 and with female predilecti on in several series (6-8). 
They occur in two diﬀ erent clinical presentati ons. The unilateral sporadic vesti bular 
schwannomas, which are not hereditary, consist of about 95% of cases. Approximately 
5% of all pati ents with vesti bular schwannomas have neurofi bromatosis type two 
(NF2), which occurs in 1 per 50,000 of the general populati on and which is generally 
found in children or young adults (9). NF2 is autosomal dominant and is characterized 
by the development of bilateral vesti bular schwannomas, peripheral schwannomas, 
meningiomas and presenile lens opaciti es. The NF2 gene has been mapped to 
chromosome 22 and is thought to be a ‘tumor suppressor gene’. Like other tumor 
suppressor genes (such as p53), the normal functi on of the NF2 gene is to stall cell 
growth and division, ensuring that cells do not divide uncontrollably. A mutati on in 
the NF2 gene impairs its functi on, and accounts for the clinical symptoms observed 
in NF2 pati ents. There are major diﬀ erences in both clinical presentati on as well as 
choice of treatment between the unilateral and bilateral tumors and therefore this 
thesis will be limited to the unilateral sporadic vesti bular schwannomas. 
Vesti bular schwannomas usually cause unilateral hearing loss, ti nnitus and 
someti mes dizziness or verti go. In larger tumors unsteadiness, trigeminal symptoms 
and long tract symptoms may arise. However, symptoms due to aﬀ ected lower cranial 
nerves are rarely seen. In very large tumors, brain stem compression, obstructi ve 
hydrocephalus and increase of intracranial pressure can also be observed. For 
many years, VS was diagnosed using standard audiometry together with auditory 
brain stem evoked responses (ABRs), which is a sensiti ve indicator of retrocochlear 
pathology, and computer tomography of the internal auditory canal. This method 
could demonstrate a widening of the porus or when contrast enhanced, a VS 
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extending into the cerebelloponti ne angle (CPA). Nowadays, contrast enhanced MRI 
using T1-weighted images, is the gold standard for diagnosing VS and tumors as small 
as 2-3 mm can be detected (10).
Vesti bular schwannoma treatment
Microsurgery
More than a century aft er Eduard Sandifort (1742-1814), professor of anatomy at the 
University of Leiden, described the fi rst presumpti ve case of VS, Sir Charles Balance 
(1856-1936) successfully operated on a VS for the fi rst ti me in 1894 (11,12). In his 
surgical report, he described the diﬃ  culti es of getti  ng his index fi nger around the 
tumor to achieve removal. But the pati ent was sti ll alive aft er surgery albeit with a 
fi ft h and seventh nerve palsy. 
Several decades later, the treatment of VS had been further developed, but sti ll 
with high operati ve mortality: for instance, at the 1913 Internati onal Conference 
of Medicine in London, the perioperati ve mortality in the major centers was 
reported at 78% and most survivors experienced signifi cant postoperati ve morbidity 
(13). However, surgical techniques conti nued to evolve with the introducti on of 
diﬀ erent surgical approaches, bett er anesthesia and use of anti bioti cs. One of the 
greatest improvements of that ti me was probably the introducti on of the operati ng 
microscope by the otologist William House in 1961. As of that ti me, the VS fi eld 
was no longer dominated by neurosurgeons like Harvey Cushing or Walter Dandy. 
Together with William Hitselberger, also a renowned neurosurgeon, House could 
further develop surgical approaches like the translabyrinthine (TL) and middle fossa 
(MF) approach. They became a unique surgical team and were thereby the founders 
of the close cooperati on between otologists and neurosurgeons in the treatment of 
VS, a cooperati on which sti ll exists today. In 1968, House reported on 141 pati ents 
with a 72% facial nerve preservati on rate. In 1978, in a subsequent series of 500 
VS pati ents, the facial nerve was anatomically preserved in 96.6% of these pati ents 
(14,15). With the use of new surgical approaches and more recently intraoperati ve 
facial nerve monitoring, it was not only possible to save the life of a pati ent suﬀ ering 
from VS, but the tumor could now be removed more radically. Moreover, important 
structures such as the facial nerve and inner ear could also be saved. 
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Nowadays, the perioperati ve mortality has become less than 1%, with favorable 
cranial nerve outcomes reported by the major centers (16-22). However, despite 
these advances, considerable risk sti ll exists to both facial nerve functi oning and 
hearing. Furthermore, microsurgery may lead to complicati ons such as postoperati ve 
intracranial haemorrhage, cerebrospinal fl uid (CSF) leak and meningiti s. 
Radiosurgery
During the evoluti on of microsurgical treatment, others were working to develop 
new concepts for tumor management. In 1969, Lars Leksell was the fi rst to treat 
vesti bular schwannomas with Gamma Knife radiosurgery at the Karolinska Hospital 
in Stockholm, Sweden (23). He proposed the technique of focusing multi ple beams 
of external radiati on on the stereotacti cally defi ned intracranial tumor. The average 
of these intersecti ng beams results in very high doses of radiati on in the tumor, but 
very low doses to non-target ti ssues along the pathway of each beam. The modern 
Gamma Knife consists of 201 fi xed cobalt radiati on sources in a fi xed hemispherical 
array, such that all 201 photon beams are focused on a single point. The pati ent 
is stereotacti cally positi oned in the Gamma Knife so that the intracranial tumor 
coincides with the isocenter of radiati on. The radiati on target volume is shaped 
conform to the intracranial tumor using beam blocking, variable collimati on and 
multi ple isocenters.
Another radiati on alternati ve for the treatment of VS is conventi onal radiotherapy 
(24). This technique, by contrast, delivers the dose to the tumor in fracti ons. The dose 
can be targeted using stereotaxy as well as conformal techniques. 
This thesis will discuss the results of radiosurgical treatment of VS using the 
linear accelerator (LINAC) system. In 1984, an alternati ve radiosurgical opti on, the 
LINAC, was fi rst described by Betti   et al (25). Since then, the precision and accuracy 
of the LINAC systems have been further improved and modifi ed for the required 
radiosurgical applicati on (26, 27) Most LINAC systems rely on the following basic 
principles: a collimated photon beam is focused on the stereotacti cally identi fi ed 
intracranial tumor. The gantry of the LINAC rotates around the pati ent, producing 
an arc of radiati on focused on the tumor. The pati ent couch is then rotated in the 
horizontal plane and another arc is performed. In this manner, multi ple non-coplanar 
arcs of radiati on intersect at the target volume and produce a high target dose, with 
minimal radiati on dose to surrounding ti ssue. The dose concentrati on method is 
analog to the multi ple intersecti ng beams of cobalt radiati on in the Gamma Knife 
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system. Again the target dose distributi on can be shaped according to the tumor 
using variable collimati on, multi ple isocentres or changing the arc angles. Dose 
distributi ons are the same for LINAC based and Gamma Knife systems. 
In the past, results from radiosurgical studies showed relati vely impaired cranial 
nerve functi ons, which were probably caused by the higher dose of radiati on to 
the tumor margin and higher target volumes. Moreover, at that ti me, radiosurgery 
was planned with early generati on CT scans with relati vely poor quality, making it 
more diﬃ  cult to dose planning to the tumor margin. At the present ti me, advances 
in dose planning soft ware and MR imaging together with a gradual decline in the 
prescribed dose of radiati on have signifi cantly improved cranial nerve outcomes, 
have reduced complicati on rates and have resulted in promising long term tumor 
control (28-34). However, there are some limitati ons to the treatment. For instance, 
the goal of treatment is to achieve tumor control and not removal, which means 
that with this technique there is no ability to relieve the mass eﬀ ect of the tumor. 
Moreover, in order to avoid complicati ons, lower and potenti ally less eﬀ ecti ve doses 
are required for higher tumor volumes. This limits the use of radiosurgery to the 
treatment of smaller tumors. Furthermore, the evidence regarding long term tumor 
control aft er low dose radiosurgery is only recently becoming available. Another 
limitati on is the need for lifelong follow-up even aft er successful treatment. Despite 
these limitati ons, there is increasing evidence that radiosurgery is a safe and eﬀ ecti ve 
alternati ve therapy for vesti bular schwannomas (28-30).
Observati on
Technical advances such as the advent of magneti c resonance imaging (MRI) 
also made it possible to detect small tumors early in pati ents with minimal or no 
symptoms. With the widespread use of MRI, the relati ve incidence of smaller tumors 
has risen signifi cantly. Moreover, increased knowledge on the natural history of 
these tumors shows that most VS are slow growing or do not grow at all (35,36). In a 
recent meta-analysis Smouha et al. found a mean growth rate of 1.9 mm/year during 
an observati on period of 3.2 years (37). Some reports also describe spontaneous 
involuti on or rather rapid growth (38,39). As a result, experts in the fi eld of skull 
base surgery have questi oned the need for major skull base surgery in every case of 
VS. Despite advances in microsurgical treatment, pati ents may be left  with defi cits, 
which are not insignifi cant and outcomes may not automati cally equate improved 
QoL. Other factors might also infl uence the decision to refrain from treatment such 
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as advanced age or severe comorbidity or the fact that the tumor is located at the 
only hearing ear. Therefore, in many centers, a more conservati ve approach has been 
proposed for small and medium-sized tumors, in which no treatment is oﬀ ered to 
the pati ents, but an initi al wait and scan surveillance unti l there is evidence of tumor 
progression or signifi cant increase of symptoms (40-44). This approach has been 
increasingly supported in the literature and obviously has great appeal for pati ents. 
However, there are some limitati ons to this kind of approach of VS. The natural 
course of the tumor is sti ll uncertain, for instance there are no predicti ve factors for 
tumor growth or progression of symptoms and delayed treatment in case of growth 
may impose greater morbidity (44). Furthermore, a wait and scan policy oﬀ ers no 
defi nite treatment and necessitates a prolonged and probably lifelong follow-up. 
Treatment decisions
As described above, VS pati ents have several treatment opti ons including observati on, 
microsurgery and stereotacti c radiosurgery. However, the treatment of VS pati ents 
is sti ll controversial with advocates and opponents of each modality. There is a large 
amount of literature supporti ng these three modaliti es, which are oft en separately 
assessed and only someti mes compared to each other. Despite this abundance, the 
evidence is generally no bett er than class III in the Cochrane classifi cati on of the quality 
of evidence (45). Thus, it appears that well-designed, randomized controlled studies 
(RCTs) are required in order to improve the quality of the evidence and compare the 
diﬀ erent modaliti es. However, the diﬃ  culty of such a study is that the three methods 
of VS management have totally diﬀ erent goals. The aim of microsurgery is complete 
tumor removal whereas radiosurgery aims to control tumor growth assuming that 
pati ents will not need additi onal treatment. Wait and scan oﬀ ers pati ents tumor 
surveillance under the assumpti on that most tumors do not grow. Unti l now, there is 
no hard evidence for any of these approaches. First, there should be some consensus 
on the goals and success criteria of treatment of VS before RCTs can be undertaken.
In general, the choice of treatment for many pati ents depends on their own 
specifi c goals and on the expected results from their treatment. Before this decision, 
every pati ent must be provided with informati on about all available treatment 
opti ons, including the advantages and disadvantages of each, as this is the basis for 
informed consent. Traditi onally, the primary outcome measures in the evaluati on 
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of treatment have evolved around mortality and morbidity. However, there is an 
increased interest concerning the impact of interventi ons on functi on and quality 
of life (QoL). QoL assessment may provide valuable informati on that is not always 
supplied by traditi onal outcome measures. It is now well recognized that treatment 
choices in individual pati ent care can be positi vely infl uenced by QoL assessment (46). 
QoL can not only help to determine pati ent preference, or compare well-being aft er 
diﬀ erent treatment modaliti es but also measure minor diﬀ erences in response to 
treatment which may be missed by the traditi onal outcome measures. 
Pati ents’ percepti ons
During the last 20 years, interest in pati ent reported outcomes (PROs) research has 
increased enormously, especially towards health status and health care interventi ons 
(46). Quality of life is an operati onalizati on of PROs and represents the sum of an 
individual’s physical, social, emoti onal, occupati onal and spiritual well-being. Defi ning 
QoL is therefore a complex matt er and a comprehensive defi niti on does not exist (47). 
The World Health Organizati on has proposed “the individual’s percepti on of their 
positi on in life in the context of the culture and value systems in which they live and in 
relati on to their goals and expectati ons, standards and concerns” (48). This approach 
is a more broad and generic conceptualizati on of QoL and can be diﬀ erenti ated from a 
more specifi c ‘health-related QoL’, which concerns those aspects of people’s lives that 
impact directly their health status or the more economic cost-eﬀ ecti veness models 
of QoL. A widely used defi niti on of ‘health-related QoL’ was proposed by Patrick and 
Erickson: “the value assigned to the durati on of life as modifi ed by the impairments, 
functi onal states, percepti ons and social opportuniti es that are infl uenced by disease, 
injury, treatment or policy” (49). More recently, Schipper et al. described health-
related QoL as: “the functi onal eﬀ ect of an illness and its consequent therapy upon 
a pati ent, as perceived by the pati ent” (50). These functi onal eﬀ ects are divided into 
three categories: physiological, psychological and social eﬀ ects, which are thought to 
adequately represent QoL.
Some of the fi rst aspects of QoL assessment were introduced in 1949 by Karnofsky, 
who used an index to evaluate treatment success in his pati ents. The Karnofsky 
Performance Status is an observer-rated measurement to assess pati ents on a 0-100 
scale (0 for ‘dead’ and 100 for ‘no evidence of disease, able to carry out normal 
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acti vity and to work’) (51). Since that ti me, a number of rati ng scales for clinicians 
have been developed, especially in the cancer research fi eld. However, over ti me 
the rati ngs on a pati ent’s QoL by others were considered as ‘surrogate’ and pati ents 
themselves were asked to provide informati on concerning aspects of their QoL (46). 
At present, PROs are considered as a recognized measure in modern health care 
research. 
In VS, QoL has long been a neglected area, given the quite low incidence compared 
with other more common diseases such as cancer. In the latt er area, QoL is assessed 
with well-designed and validated measures and QoL has become a major outcome 
variable, which also aﬀ ects the choice of medical management (52). However, since 
the beginning of the 1990s, QoL in VS has received increasing att enti on. One of 
the fi rst studies on PRO was performed by Wiegand et al. in 832 VS pati ents who 
had joined a pati ent member organisati on, the Acousti c Neuroma Associati on, 
aft er microsurgical treatment between 1973 and 1983 (53). Results showed that 
microsurgery has a signifi cant impact on a pati ent’s quality of daily life and that 
facial nerve dysfuncti on and hearing loss were the most diﬃ  cult aspects to cope 
with postoperati vely. However, the authors also recognized that one of the major 
limitati ons of their study was the pati ent sample itself, which consisted of operated 
VS pati ents who had joined the self-help group. On the other hand, this group may 
represent the majority of pati ents that underwent VS surgery in this period and 
therefore the results may sti ll refl ect an average VS populati on aft er surgery. The 
results of this study have led to numerous studies on the eﬀ ects of microsurgery on 
QoL (54-63). Most of these were performed using a retrospecti ve design and the QoL 
measures used were oft en not reliable or had not previously been used. However, 
some did use validated questi onnaires such as the Short-Form 36 Health Survey (SF-
36) or Glasgow Benefi t Inventory (GBI) (60-63). They found that QoL was generally 
impaired aft er microsurgical treatment. Interesti ngly, facial nerve functi on only 
correlated weakly with impaired QoL whereas balance problems and hearing loss 
most aﬀ ected quality of functi oning. 
Valid and reliable measures are necessary to assess QoL. A widely used and 
reliable measure of generic QoL is the SF-36, which has proven its reliability in a 
variety of diseases throughout diﬀ erent pati ent populati ons. It assesses QoL in 8 
domains and measures physical, psychological and social well-being. However, the 
sensiti vity of such a generic measure to otolaryngologic interventi ons or audiologic 
or vesti bular symptoms has been questi oned (64). Disease-specifi c measures have 
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been developed, therefore, in order to parti cularly assess QoL of pati ents with a 
specifi c disease. Unfortunately, a validated disease-specifi c questi onnaire has not 
been developed specifi cally for VS pati ents yet. However, there are some studies 
that use validated questi onnaires addressing symptoms that are typically observed 
in (treated) VS pati ents (56-59). Again, most of these studies were performed 
retrospecti vely; they generally demonstrated a negati ve eﬀ ect of surgery on the 
subsequent symptoms and on QoL. Sti ll, there is a need for validated disease-specifi c 
questi onnaires, which might be combined with generic questi onnaires in the future. 
Unti l now, only a few studies report on QoL aft er radiosurgery or conservati ve 
treatment and reports comparing diﬀ erent modaliti es are scarce (61,65-70). When 
compared to microsurgical pati ents, pati ents treated with radiosurgery appear to 
have a bett er QoL outcome. For instance, in the study by Régis, a bett er QoL was 
reported aft er Gamma Knife surgery, but the QoL measures were not validated 
(67). However, Myrseth et al. found bett er QoL aft er Gamma Knife treatment when 
compared to microsurgical treatment using validated questi onnaires (68). Surprisingly, 
litt le is known concerning QoL in untreated VS pati ents (71). Generally, impaired 
QoL is found for the three treatment modaliti es. However, oft en one can questi on 
whether the reducti on is caused by the treatment, by suﬀ ering from the tumor, or 
by both. Both prospecti ve studies with pretreatment QoL data or informati on from 
untreated pati ent samples may be valuable in answering this hypothesis. 
Another interesti ng subject is how pati ents perceive their illness and how 
they cope with having an intracranial tumor. Given the quite solid status of QoL 
as an outcome measure in medicine, researchers and clinicians started examining 
determinants of QoL. This line of research, and its clinical applicati on, might help to 
develop interventi ons that improve QoL. One concept that was found to contribute 
to variati on across pati ents in their QoL was that of illness percepti ons (72). Illness 
percepti ons (IPs) pertain to the idiosyncrati c ideas (cogniti ons) of pati ents (and 
physicians) regarding complaints and symptoms. They seem to play a role in the 
variati on in QoL experienced by pati ents. IPs include the beliefs and att ributi ons 
pati ents have regarding their illness and specifi cally regarding symptoms, causes, 
consequences, and the ti me the illness will last (73). They are assessed with 
questi onnaires, drawings or even clay representati ons of an illness (74). IPs precede 
coping behavior, and in turn, coping determines QoL (75). IPs have been found to be 
relevant in virtually any physical disorders, and, increasingly in psychiatric disorders. 
IPs refl ect the relevance and importance of how pati ents make sense of complaints, 
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illness and medical treatment – irrespecti ve of objecti ve medical knowledge. In this 
way, including IPs in QoL research strengthens the biopsychosocial model, which is 
parti cularly relevant in medical care for pati ents with a chronic illness. In pati ents 
with VS, IPs have not yet been studied before. Our current study, therefore, explores 
the relevance of IPs in pati ents with VS, and their contributi on to, hopefully and 
possibly, an even bett er quality of care, and QoL. 
Overview and aims of the present thesis
In the Netherlands, VS was previously described in a PhD thesis by Jos van Leeuwen, 
who reported on the diagnosti c aspects and results of surgery in parti cular. The 
studies were performed at the Department of Otolaryngology at the University 
Hospital Nijmegen between 1980 and 1993 and van Leeuwen was one of the fi rst 
who discussed the importance of QoL research aft er (surgical) treatment for VS (76). A 
more histopathological approach was described by Ernesti ne Sti pkovits who provided 
more insight in the natural course of VS (35) in her PhD thesis, enti tled “Vesti bular 
schwannomas, aspects of biological behavior” at the University of Utrecht in 2000.
In Leiden, pati ents with VS have been treated for many years. In the past, VS 
pati ents were primarily referred to the Department of Neurosurgery of the Leiden 
University Medical Centre (LUMC). One of the main reasons was that pati ents used 
to be operated either via the retro-sigmoid (RS) or suboccipital approach (SO) and 
that the experience of the otolaryngologists in our department was generally limited 
to the translabyrinthine (TL) approach. However, in 1996 the Leiden Skull Base 
Pathology Meeti ng (SBP) was founded, which mainly consisted of otolaryngologists, 
neurosurgeons and neuroradiologists from the LUMC. This multi disciplinary meeti ng 
provided the basis for the close cooperati on between otolaryngologists and 
neurosurgeons in VS, which sti ll conti nues to evolve. Our department was not only 
increasingly involved in the management of these tumors but also became more 
skilled in the various surgical approaches such as the TL and middle fossa (MF) 
approach. As a result, all the three main approaches: TL, RS and MF are now widely 
used in our center. However, the advantages of the TL approach are increasingly 
recognized by both our otolaryngologists and neurosurgeons and it has now become 
the most frequently used approach and ‘workhorse’. Furthermore, relati vely new 
treatment opti ons such as wait and scan or stereotacti c irradiati on have also made 
their way into our decision process over ti me. Nowadays, almost 1000 new VS 
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pati ents have been admitt ed to the LUMC and about 400 have been operated via 
the TL route.
Over ti me, our (surgical) treatment also conti nued to advance, because of 
improved techniques such as the high resoluti on MRI, the facial nerve monitor, CUSA 
aspirator and bett er perioperati ve care. As obvious as it may seem, we recognized that 
the treatment of any conditi on can only be justi fi ed when the results of treatment 
are bett er than the natural course of the disease. There is a growing debate on how 
VS can be best treated as it has become clear that the tumor may remain unchanged 
for many years. In an eﬀ ort to contribute to this debate, QoL research was initi ated 
at our department in 2001.
Our study assesses QoL in order to facilitate treatment choices in individual 
pati ent care, contributes to the determinati on of the best use of treatments and 
evaluates QoL in our VS pati ent populati on. It is likely that none of the three 
treatment modaliti es on its own is the best opti on for all individuals. Knowledge of 
the clinical and QoL eﬀ ects of each of the diﬀ erent opti ons can help clinicians to 
outline the choices available to pati ents and assist them in selecti ng which is best 
for them. For instance, if a VS pati ent has a small tumor with minimal symptoms, 
reasonable treatment opti ons might be radiosurgery or wait and scan. The treatment 
choices available depend partly on the pati ent’s age and comorbidity but also, to 
some extent, on the individual’s preferences given the diﬀ erent QoL implicati ons of 
the two treatments. Some pati ents may choose radiosurgery with possible surgical 
risks in the short term. Others will prefer no acti ve treatment or subsequent risks and 
choose to evaluate their tumor periodically by MR imaging. Informati on on QoL in 
this context can be useful to both professionals and pati ents when considering what 
to expect, given certain health conditi ons and treatments. This kind of evidence to 
inform a clinician or pati ent comes from studies of populati ons of pati ents who are 
experiencing the conditi on or treatment (46). 
This thesis describes QoL and clinical features in pati ents with VS at their diagnosis 
and aft er treatment with three diﬀ erent modaliti es: observati on, microsurgery or 
radiosurgery. 
20 | Chapter 1
Outline of the thesis
Chapter two prospecti vely assesses QoL together with illness percepti ons (IPs) and 
coping behavior in a series of 90 consecuti ve, untreated VS pati ents. QoL assessment 
was performed at the moment of diagnosis, which enabled us to assess the burden 
of suﬀ ering from an (untreated) VS. The results were compared to pati ents with 
other serious or chronic illnesses (i.e. head and neck cancer pati ents or pati ents with 
chronic obstructi ve pulmonary disease) in order to assess what kind of IPs and coping 
behavior could be expected with these kinds of pati ents. 
Chapter three describes a group of VS pati ents with small- and medium-sized 
tumors who were observed for almost four years. Failure of conservati ve treatment, 
tumor progression and development of symptoms such as hearing are described. 
QoL outcomes at baseline and at the end of follow-up are compared in those pati ents 
who were sti ll included in our protocol. An initi al conservati ve approach, in which the 
tumor is watched rather than treated, is an att racti ve opti on to many VS pati ents. 
However, there is no clarity about the natural course of the disease such as tumor 
growth, preservati on of hearing or QoL.
Unti l recently, microsurgery was considered the ‘gold standard’ in the treatment 
of VS. However, at present stereotacti c irradiati on is increasingly becoming a fi rst 
treatment opti on for VS. Chapter four presents clinical and QoL results of 64 pati ents 
with VS aft er low dose linear accelerator based (LINAC) radiosurgery. This multi center 
study is performed in collaborati on with the Erasmus University Medical Centre in 
Rott erdam. Both clinical results and QoL outcome are compared to existi ng results 
and norm populati ons. 
Chapter fi ve describes the eﬀ ect of verti go on QoL in 18 VS pati ents using generic 
and a disease-specifi c questi onnaire for verti go. Of the cochleovesti bular symptoms 
in VS, verti go is thought to aﬀ ect QoL most (71). Verti go may increasingly cause 
anxiety, depression and impaired functi oning during physical and social acti viti es 
and may therefore have a severe negati ve eﬀ ect on quality of daily functi oning of VS 
pati ents. Despite the signifi cant impact on QoL, there is litt le evidence with regard 
to any interventi ons in VS pati ents with these symptoms. In an att empt to relieve 
pati ents from their verti go and improve QoL, we performed translabyrinthine (TL) 
surgery and preoperati ve and postoperati ve results are evaluated. 
The eﬀ ects of postoperati ve facial nerve impairment on QoL sti ll remain unclear. 
Some studies report a signifi cant negati ve eﬀ ect on QoL, whereas others do not. 
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However, it is well recognized that pati ents with facial nerve paralysis experience 
signifi cant functi onal and psychological morbidity (77,78). In order to reanimate the 
paralyzed facial musculature aft er (surgical) trauma, there are various treatments, 
which consist of stati c and non-stati c procedures (79-83). The technique that is most 
frequently used involves a variati on of the facial-hypoglossal nerve coaptati on with 
or without stati c procedures. Chapter six presents a new variati on to the facial-
hypoglossal technique (FHT) to restore facial nerve paralysis as a result of (surgical) 
trauma. QoL and functi onal improvements are described and compared to results 
from other comparable techniques. 
Facial nerve functi on is one of the most important factors defi ning success of 
treatment for both the pati ent and surgeon. In case of microsurgical treatment, the 
surgeon therefore may decide to leave some of the tumor in situ in order to preserve 
facial nerve functi on and maintain QoL, especially in large tumors. Intraoperati ve 
assessment of the extent of tumor removal, however, lacks objecti vity. Objecti ve 
assessment of the actual extent of removal documented with postoperati ve 
gadolinium enhanced magneti c resonance imaging (MRI) scans is therefore 
necessary, but is scarcely provided. Chapter seven examines the hypothesis that 
postoperati ve facial nerve functi on should be signifi cantly bett er when residual tumor 
is deliberately left  behind. We also objecti vely assess the extent of the removal using 
gadolinium-enhanced MRI scans and compare results with the extent of the removal 
as intraoperati vely esti mated by the surgeon. 
Chapter eight discusses our major results and conclusions of the studies in this 
thesis and presents clinical implicati ons and suggesti ons for future research. 
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Abstract
Objecti ve: To evaluate illness percepti ons, coping behavior, and quality of life in 
pati ents with vesti bular schwannoma at diagnosis.
Study design: Prospecti ve pati ent analysis.
Setti  ng: University Teaching Hospital, terti ary care clinic.
Pati ents: Consecuti ve pati ents with vesti bular schwannoma (n = 79) completed a set 
of questi onnaires at diagnosis in order to assess psychological characteristi cs and 
quality of life. 
Interventi on: Diagnosti c and rehabilitati ve.
Main outcome measures: Psychological characteristi cs and quality of life, measured 
via questi onnaires focusing on illness percepti ons (Illness Percepti on Questi onnaire 
Revised), coping (Utrecht Coping List), and quality of life (SF-36), were compared to 
normati ve data for the general Dutch populati on and to data concerning pati ents 
with other illnesses.
Results: The SF-36 scores of vesti bular schwannoma pati ents at diagnosis were 
signifi cantly decreased when compared to healthy controls, pati ents with head and 
neck cancer, benign prostate hypertrophy (BPH), chronic obstructi ve pulmonary 
disease (COPD), and deaf pati ents. Scores for illness percepti ons were in between 
those of pati ents with acute pain and chronic pain for most subscales, except illness 
identi ty, emoti onal representati ons, and illness coherence. In their coping behavior, 
vesti bular schwannoma pati ents scored lower on the subscale acti ve coping, sought 
less social support, and expressed their emoti ons less, but also showed less passive 
coping compared to reference values. 
Conclusions: Vesti bular schwannoma pati ents experience impaired quality of life 
compared to healthy controls and reference groups. Their illness percepti ons are in 
between those of pati ents with acute and chronic pain, and their coping behavior 
is less acti ve in general. This may have implicati ons for clinical decision making and 
for opti mizing interacti on with pati ents. Changing illness percepti ons and coping 
by means of an interventi on and encouraging social support by means of pati ent 
support groups may improve quality of life in vesti bular schwannoma pati ents.
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Introducti on
In modern medicine, pati ent-reported outcomes are increasingly viewed as central 
in evaluati ng medical care. Quality of life (QoL) is an operati onalizati on of pati ent-
reported outcomes and is defi ned as “the functi onal eﬀ ects of an illness and its 
treatment, as perceived by the pati ent” (1). There is overwhelming evidence for the 
fi nding that objecti ve characteristi cs of an illness are hardly associated with QoL. 
QoL seems to be analyzed mainly via social, psychological, and pati ent-health care 
provider characteristi cs.
The idea of illness percepti ons is one such psychological characteristi c (2). 
Illness percepti ons pertain to the idiosyncrati c ideas (cogniti ons) of pati ents (and 
physicians) regarding complaints and symptoms. They seem to play a role in the 
variati on in QoL experienced by pati ents. Illness percepti ons include the beliefs and 
att ributi ons pati ents have regarding their illness and specifi cally regarding symptoms, 
causes, consequences, and the ti me the illness will last. This informati on is most 
oft en not directly asked for in a clinical setti  ng. However, research shows that illness 
percepti ons partly analyze the severity of disease experienced by the pati ent (QoL) 
and outcome (3,4).
Coping behavior is the behavior one shows in reacti on to adversity in life, whether 
it is coping with illness or with something simpler such as, for example, a fl at ti re. It is 
thought that this coping behavior may aﬀ ect the percepti on of QoL. An acti ve coping 
style is associated with bett er QoL and bett er outcome, whereas a general passive 
coping style is associated with worse QoL and outcome. Seeking social support and 
expressing emoti ons, also part of coping behavior, have been shown to be important 
in achieving good QoL (5). 
In current literature, an increasing amount of studies concerning other illnesses in 
diﬀ erent medical fi elds focus on QoL issues. Of these illnesses, several QoL reference 
groups were chosen on the basis of both clinical relevance and availability. In clinical 
practi ce, otorhinolaryngologists are familiar with head and neck cancer pati ents 
as well as deaf pati ents. Therefore, it may be interesti ng to see whether vesti bular 
schwannoma (VS) pati ents have bett er or worse QoL than these 2 other pati ent 
groups. Furthermore, pati ents who have benign prostate hypertrophy (BPH) are 
similar to VS pati ents in that they both have a benign, slow-growing tumor that may 
cause quite bothersome symptoms. Chronic obstructi ve pulmonary disease (COPD) 
pati ents were chosen because they have a chronic disease causing many limitati ons 
and handicaps in daily life. 
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For the Utrecht Coping List (UCL), reference groups were chosen based on 
availability and comparability, apart from populati on norms. Pati ents with chronic 
pain were chosen because of the chronic character of their medical conditi on, which 
may be considered more chronic and thus less acute than recently diagnosed VS. 
Pati ents undergoing bone marrow transplantati on were chosen because they have 
a serious life-threatening conditi on. Utrecht Coping List scores for head and neck 
cancer pati ents; deaf pati ents; or pati ents with BPH, COPD, or acute pain were not 
available. 
As in other fi elds, QoL is a much studied topic in VS pati ents. Most studies are 
retrospecti ve, and they consistently report QoL to be lower than in specifi ed norm 
groups, usually postt reatment (6-16). In some of these studies, verti go is found to 
be the major symptom aﬀ ecti ng QoL (17,18). No study to date has evaluated illness 
percepti ons or coping in VS pati ents (19). Very few studies have evaluated QoL in VS 
pati ents before treatment or before proposal to treatment (18,19). Therefore, the 
aim of this study was to evaluate QoL, illness percepti ons, and coping behavior in 
pati ents with VS at diagnosis before proposal to treatment. 
Materials and Methods
Pati ents 
Between January and October 2005, 90 consecuti ve pati ents were newly diagnosed 
with VS. All these pati ents received a set of questi onnaires accompanied by a lett er 
informing them of the purpose of the study and instructi ons on how to complete the 
questi onnaires. Pati ents were included before treatment and treatment proposal. 
Seventy-nine pati ents completed and returned the set of questi onnaires (87.8%). Six 
refused due to personal problems, 4 did not respond, and 1 responded anonymously. 
Thirty-six pati ents were men (45.6%), and mean age was 57.7 years (25.8-78.7 
yr). According to the hearing classifi cati on system of the Committ ee on Hearing 
and Equilibrium (20), hearing was 20.5% Class A, 30.8% Class B, 23.1% Class C, and 
25.6% Class D. Tinnitus was experienced by 64.6% of pati ents, and 38% experienced 
unsteadiness, defi ned as balance disorder. Eight of these pati ents and 2 others (total 
of 12.7%) experienced verti go, defi ned as a paroxysmal spinning sensati on, oft en 
with nausea and vomiti ng. The average durati on of symptoms was 1 to 5 years. 
The trigeminal nerve was intact in 92.4% of pati ents, and all pati ents but 1 (98.7%) 
had House-Brackmann Grade I of the facial nerve. Thirty-eight percent of tumors 
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were strictly intracanalicular, and mean extracanalicular tumor size was 14.62 mm 
measured with MRI (Table 1).
Table 1. Characteristi cs of pati ents with VS.
Responding pati ents (%)
n = 79
Non-responding pati ents (%)
n = 11
Sex, men 36 (45.6) 5 (45.5)
Age, yr (mean, (range)) 57.7 (25.8-78.7) 56.9 (29.9-78.5)
Hearing
Class A 16 (20.5) 2 (20)
Class B 24 (30.8) 3 (30)
Class C 18 (23.1) 4 (40)
Class D 20 (25.6) 1 (10)
Symptoms
Tinnitus 51 (64.6) 9 (81.8)
Unsteadiness 30 (38) 5 (45.5)
Verti go 10 (12.7) 1 (9.1)
Headache 5 (6.3) 0 (0.0)
Earache 3 (3.8) 0 (0.0)
Durati on of symptoms
0-6 mo 15 (19.0) 1 (9.1)
7-12 mo 17 (21.5) 1 (9.1)
1-2 yr 9 (11.4) 1 (9.1)
2-5 yr 21 (26.6) 5 (45.5)
5-10 yr 7 (8.9) 2 (18.2)
>10 yr 10 (12.7) 1 (9.1)
Status of cranial nerves
N V unaﬀ ected 73 (92.4) 10 (90.9)
N VII unaﬀ ected (H-B I) 78 (98.7) 11 (100)
Unaﬀ ected 71 (89.9) 10 (90.9)
Tumor characteristi cs
Intracanalicular 30 (38.0) 3 (27.3)
Size (extracanalicular), mean 
(SD)
14.62 (8.36) 14.88 (8.01)
Cysti c component 6 (7.5) 2 (18.2)
Pati ent characteristi cs of responding and non-responding pati ents were similar. H-B I indicates House-
Brackmann Grade I; N V, trigeminal nerve; N VII, facial nerve; SD, standard deviati on.
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Methods
The Medical Outcomes Study 36-Item Short Form Health Survey
The SF-36 is the most widely used questi onnaire to assess QoL and has been validated 
and proven to be a reliable instrument to measure QoL in general (21). It consists of 
36 items comprising 8 subscales of QoL. These subscales are 1) physical functi oning 
and 2) social functi oning, that is, the degree of limitati ons experienced in daily life 
physically and socially, respecti vely; 3) physical role limitati ons and 4) emoti onal role 
limitati ons, that is, limitati ons in work or other daily acti viti es due to physical and 
emoti onal problems, respecti vely; 5) mental health, the degree of depression and 
anxiety; 6) vitality, the degree of energy and exhausti on; and 7) bodily pain and 8) 
general health quanti fy the subjecti ve evaluati on of the pati ent’s own health status 
and pain. Higher scores indicate bett er perceived QoL. Data on pati ents’ responses 
were scored according to the instructi ons on scoring syntax in the SF-36 manual (22). 
Dutch populati on norms are available for reference. 
The Illness Percepti on Questi onnaire Revised
The Illness Percepti on Questi onnaire Revised (IPQ-R) consists of 3 parts measuring 1) 
illness identi ty, 2) cogniti ve and emoti onal representati ons, and 3) causal att ributi ons 
(i.e., causes pati ents hold responsible for their illness), with the parts containing 28, 
38, and 18 items, respecti vely. Answers are to be chosen from a 5-point Likert scale 
(strongly disagree to strongly agree) or from a yes-no scale. Scores are calculated 
over 8 dimensions of illness percepti on. These 8 dimensions are 1) illness identi ty, 
concerning the number of symptoms att ributed to the illness; 2) ti meline acute/
chronic and 3) ti meline cyclical concern strongly held beliefs regarding the chronicity or 
cyclical nature of the conditi on; 4) consequences concern the negati ve consequences 
of the conditi on, where higher scores represent negati ve beliefs; high scores on 5) 
personal control and 6) treatment control, refl ecti ng the perceived controllability 
of the illness, and 7) illness coherence, representi ng personal understanding of the 
conditi on; indicate positi ve beliefs; high scores for 8) emoti onal representati ons 
correspond with a greater likelihood to seek medical care. Causal att ributi ons are 
evaluated by category: psychological, risk factor, immunologic, accident, or chance. 
These causal att ributi ons indicate which factors pati ents hold responsible for causing 
their illness: psychological factors, risk factors that is smoking, immunologic factors, 
or merely bad luck (accident or chance). Mean values for pati ents with various 
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medical disorders, including chronic pain and acute pain, for pati ents with head and 
neck cancer, and for pati ents with COPD are available for comparison (23-25). For 
deaf pati ents or BPH pati ents, IPQ-R scores were not available. Because the general 
populati on is not assumed to have an illness, there are no IPQ-R norm values for the 
general populati on. Scores of pati ents with chronic pain and acute pain may be used 
instead. 
Utrecht Coping List
The UCL consists of statements concerning 7 diﬀ erent coping styles: acti ve coping 
(disentangling the situati on and purposefully working to solve the problem), 
seeking distracti on (seeking distracti on not to have to think regarding the problem), 
avoidance (leaving the problem to what it is or running away from it), seeking social 
support (seeking comfort and understanding from others), passive coping (being 
completely overwhelmed by the problem), expressing emoti ons (showing irritati on 
and anger regarding the problem), and fostering reassuring thoughts (opti mism). Of 
47 statements, pati ents indicate whether they fi nd these applicable to themselves on 
a 4-point scale ranging from “seldom or never” to “very oft en”. Higher scores indicate 
greater aﬃ  nity with specifi c coping styles. Dutch populati on norms are available for 
the general populati on aged 19 to 65 years, as well as for pati ents with chronic pain 
and for pati ents undergoing bone marrow transplantati on (5,26,27).
Reference Populati ons
For the SF-36, reference populati ons consisted of pati ents with head and neck cancer, 
BPH, COPD, and deaf pati ents. In the reference study by Funk et al. (28), 180 head and 
neck cancer pati ents were included with a mean age of 58.9 years. Exclusion criteria 
were recurrent disease, cutaneous cancers, lymphomas, sarcomas, and thyroid or 
parathyroid tumors. Sex distributi on was not menti oned, clinical American Joint 
Committ ee on Cancer stage at diagnosis was Stage I (13%), Stage II (17%), Stage III 
(18%), Stage IV (50%), or unknown (2%). 
The study by Salinas Sanchez et al. focused on BPH in 181 men with a mean age 
of 68.8 years and undergoing surgery for prostate-related symptoms (29). Of these 
pati ents, 103 had objecti ve symptoms such as urine retenti on.
Geijer et al. (30) conducted a study on COPD pati ents. The study populati on 
consisted of 395 male smokers with a mean age of 55.4 years due to a higher 
prevalence of COPD in men and limited study resources. Disease severity in COPD 
34 | Chapter 2
is measured with the Global Initi ati ve for Chronic Obstructi ve Lung Disease (GOLD) 
classifi cati on. In the study populati on, 69.7% did not have any airfl ow limitati on, 
29.6% had mild disease (GOLD I), and 10.6% had moderate disease (GOLD II).
The SF-36 scores of 27 deaf pati ents were analyzed by Mo et al. (31). Postlingually 
deafened adult cochlear implant candidates were included, of which there were 12 
men and 15 women. In 14 of these pati ents, the cause of deafness was unknown. The 
other pati ents had hereditary deafness, otosclerosis, meningiti s, Ménière disease, 
trauma, or rubella. 
For the IPQ-R, reference populati ons consisted of pati ents with head and neck 
cancer or COPD. Scharloo et al. (24) included 68 pati ents with head and neck cancer 
with a mean age of 60 years, of which 70% were men. Pati ents were excluded if 
they were mentally retarded or demented, or unable to fi ll in the questi onnaires for 
other reasons. American Joint Committ ee on Cancer staging was I (11 pati ents), II (15 
pati ents), III (12 pati ents), or IV (30 pati ents). The IPQ-R scores of 171 COPD pati ents 
were evaluated in another study by Scharloo et al. (25). Mean age of this populati on 
was 66 years, with 112 men and 59 women. Pati ents were excluded if they had other 
signifi cant disabling diseases that would confound symptom reporti ng and QoL 
scoring. Disease severity of COPD was moderate (GOLD II) in 84 pati ents and severe 
(GOLD III) in 87 pati ents.
The fi rst UCL reference populati on was studied by Hopman-Rock et al. (26) and 
consisted of 59 pati ents with chronic pain aged 63.7 years on average. Twenty-
fi ve percent of pati ents were men. Pati ents were excluded if they parti cipated in 
another substudy of the Rott erdam study, had cogniti ve impairments, or were living 
in a home for the elderly. The second reference populati on consisted of 123 bone 
marrow transplant pati ents studied by Broers et al. (27). Mean age at bone marrow 
transplantati on was 35.4 years. Of these pati ents, 74 were men and 49 were women. 
Pati ents were excluded if their IQ was too low or if their data were incomplete. 
Indicati ons for treatment were acute leukemia (52%), chronic myelogenous leukemia 
(17.1%), or lymphoma (30.9%).
Stati sti cal Analysis
Means were calculated for subscales of all questi onnaires and compared with 
available Dutch populati on norms by Student’s t-tests. If available, means were 
also compared with means of pati ents with comparable illnesses. Signifi cance was 
calculated with a 99% confi dence interval. A signifi cance level of 0.01 was used to 
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adjust for multi ple testi ng. Analyses were performed with the Stati sti cal Package for 
the Social Sciences (SPSS 14.0 for Windows). 
Results
In summary, when compared with pati ents with other illnesses, VS pati ents showed 
signifi cantly lower QoL scores for almost all subscales except physical functi oning. 
Mental health was only bett er in deaf pati ents and pati ents with COPD, whereas 
perceived general health was bett er for all pati ent groups except for men with BPH 
(Table 2). 
Compared with pati ents with acute pain, VS pati ents scored signifi cantly higher 
on the ti meline (acute/chronic) subscale of the IPQ-R, indicati ng that they considered 
their illness to be more chronic than pati ents with acute pain. However, VS pati ents 
had a signifi cantly lower sense of personal control and treatment control. They did 
not diﬀ er signifi cantly in illness identi ty, in the belief in a cyclical character of their 
illness, or in emoti onal representati ons. Compared with pati ents with chronic pain, 
VS pati ents scored signifi cantly lower on the ti meline (acute/chronic) subscale, 
indicati ng that they considered their illness to be more acute than pati ents with 
chronic pain. Moreover, they had a signifi cantly higher sense of treatment control 
and a signifi cantly more coherent view regarding their illness. For personal control 
and psychological att ributi ons, there were no signifi cant diﬀ erences in scores. 
VS pati ents signifi cantly thought of their illness as a more chronic problem and 
had a signifi cantly greater sense of illness coherence compared with pati ents with 
recently diagnosed head and neck cancer. VS pati ents had signifi cantly lower scores 
for emoti onal representati ons and expected their illness to have signifi cantly less 
consequences to their lives compared with pati ents with head and neck cancer. 
Pati ents with COPD att ributed more symptoms to their illness (illness identi ty) 
and thought that their illness would be chronic and cyclical signifi cantly more than 
VS pati ents. They considered their illness to have greater consequences to their 
lives and had a higher sense of personal control, whereas they had a lower sense of 
treatment control compared with VS pati ents. Higher scores on the fi rst 5 subscales 
may be associated with less favorable outcomes compared with higher scores on the 
last 3 subscales. Regarding the cause of their illness, 23.8% of VS pati ents reported 
chance or bad luck was the cause of their illness. Most pati ents (52.5%) could not 
point out 1 specifi c item as a possible cause of their illness (Table 3). 
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Coping styles of VS pati ents diﬀ ered signifi cantly from coping behavior of the 
average Dutch populati on. VS pati ents showed less acti ve coping, but also less passive 
coping; they sought less social support; and expressed their emoti ons, that is, showed 
irritati on and anger regarding problems, less compared with populati on norms. 
Compared with pati ents with chronic pain, VS pati ents were less avoiding toward 
problems, sought more social support, showed less passive coping, and fostered 
fewer reassuring thoughts. Pati ents undergoing bone marrow transplantati on 
expressed their emoti ons signifi cantly more than VS pati ents but fostered less 
reassuring thoughts (Table 4). 
Table 3. Comparison of IPQ-R scores in VS pati ents to other populati ons. 
IPQ-R
VS
n = 80
AP
n = 35
CP
n = 63
HN
n = 68
COPD
n = 171
Illness identi ty 2.21 (2.44) 2.81 (1.73) 6.19 (2.81)* 2.32 (2.49) 5.62 (2.86)*
Timeline 
(acute/chronic)
20.62 (3.99) 13.4 (5.38)* 23.12 (4.41)* 17.12 (4.35)* 26.66 (4.41)*
Timeline (cyclical) 10.59 (3.78) 9.37 (2.58) 12.87 (3.89)* 9.92 (3.06) 12.13 (4.88)*
Consequences 16.41 (2.05) 14.23 (4.44)* 23.45 (3.89)* 19.43 (4.28)* 19.25 (6.05)*
Emoti onal 
representati ons
15.33 (3.93) 16.12 (4.03) 19.75 (4.15)* 19.21 (5.54)* 14.13 (7.03)
Personal control 19.08 (2.62) 22.94 (3.52)* 18.42 (4.01) 18.77 (3.78) 22.44 (5.89)*
Treatment control 16.92 (2.96) 19.43 (3.28)* 14.22 (3.36)* 17.46 (2.86) 14.29 (3.74)*
Illness coherence 18.1 (3.6) 9.31 (3)* 13.37 (4.78)* 15.79 (3.78)*
Mean (standard deviati on). Diﬀ erences between means were tested with Student’s t-tests. Higher scores 
on the fi rst 5 subscales may be associated with less favorable outcomes compared with higher scores on 
the last 3 subscales.
*p < 0.01 compared with VS pati ents.
AP indicates pati ents with acute pain (23); COPD, pati ents with chronic obstructi ve pulmonary disease 
(25); CP, pati ents with chronic pain (23); HN, head and neck cancer pati ents (24); IPQ-R indicates Illness 
Percepti on Questi onnaire Revised; VS, vesti bular schwannoma pati ents.
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Table 4. Comparison of VS UCL scores to other populati ons.
UCL
VS
n = 79
DN
n = 55
CP
n = 299
BM
n = 21
Acti ve coping 17.4 (3.9) 19.2 (3.7)* 16.4 (4.2) 17.5 (3.3)
Seeking distracti on 16.9 (3.6) 18.3 (3.1) 16.8 (3.9) 16 (3.7)
Avoiding 15 (2.9) 15.8 (3.5) 16 (3.1)* 15.3 (2.1)
Seeking social support 12 (2.9) 14.9 (4.2)* 10.2 (2.9)* 12.7 (3.2)
Passive coping 9.9 (2.5) 12.5 (2.7)* 11.7 (3.8)* 9.2 (2.4)
Expressing emoti ons 4.9 (1.5) 7 (1.8)* 5.3 (1.7) 6.1 (1.7)*
Fostering reassuring thoughts 12.4 (2.3) 13.2 (2.7) 13.3 (3.2)* 10.7 (1.9)*
Mean (standard deviati on). Diﬀ erences between means were tested with Student’s t-tests.
*p < 0.01 compared with VS pati ents. CP indicates pati ents with chronic pain (26); DN, Dutch populati on 
norms (5); BM, bone marrow transplant pati ents (27); UCL, Utrecht Coping List; VS, vesti bular 
schwannoma pati ents.
Discussion
As expected, on the basis of previous studies, QoL in Dutch VS pati ents before 
treatment was decreased compared with Dutch populati on norms (19). Because 
pati ents were included consecuti vely before treatment and treatment proposal, 
treatment modality did not induce bias in QoL, and apparently, QoL is reduced 
independently of treatment: microsurgery, radiosurgery, or wait and scan policy. 
Surprisingly, VS pati ents were shown to perceive a lower QoL than all other 
pati ent groups. Even pati ents with recently diagnosed head and neck cancer had 
higher scores for QoL, whereas their life expectancy may be much shorter than that 
of VS pati ents. Keeping in mind that most VS pati ents (79.5%) did not have Class A 
hearing, it was striking that their QoL was sti ll signifi cantly lower than that of deaf 
pati ents before cochlear implant. Quality of life of men with another benign yet 
bothersome “tumor”, BPH, was not similar to QoL of male VS pati ents. Coping with 
breathlessness (COPD) apparently does not decrease QoL as much as coping with 
VS. Apparently, VS pati ents are a group of pati ents that suﬀ er from the moment of 
diagnosis. 
The observati on that illness percepti ons of VS pati ents were in between those of 
pati ents with acute and chronic pain was not unexpected. Shortly aft er diagnosis, 
pati ents may have experienced their illness as acute in one way, whereas they may 
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have realized that the tumor in their head would infl uence their daily lives for some 
ti me. In that sense, they may have viewed their illness, albeit recently diagnosed, as 
chronic. Pati ents with head and neck cancer considered their illness less chronic, but 
they expected more consequences to their lives, which could possibly be explained 
by their altered life expectancy. Among other factors, pati ents with COPD diﬀ ered 
from VS pati ents in a stronger illness identi ty and a greater sense of personal control. 
This could be explained by the symptoms of COPD that may be more easily related 
to the illness than symptoms to VS, and that behavior such as smoking or physical 
acti vity may have a direct infl uence on the symptoms experienced. 
The most striking diﬀ erence in coping behavior compared with reference values 
was the decrease in seeking social support and expressing emoti ons. This may cause a 
decrease in QoL because seeking less social support may probably result in receiving 
less social support. It was obvious that VS pati ents showed a more acti ve and, thus, 
hopefully, more eﬀ ecti ve way of coping than pati ents with chronic pain. This may be 
explained by the durati on of illness, which is much shorter in pati ents with newly 
diagnosed VS. Therefore, it may be important to ensure that coping behavior of VS 
pati ents does not diminish to the level of pati ents with chronic pain.
Putti  ng this all together, VS pati ents experienced a decreased QoL with illness 
percepti ons and coping behavior that could be expected with their type of illness. 
However, in general, the perceived QoL of VS pati ents was signifi cantly lower than 
QoL of pati ents we compared it to. This demonstrates the need for a method to 
improve QoL in VS pati ents. 
In pati ents who had myocardial infarcti on, it was found that interventi ons aimed 
at changing illness percepti ons positi vely infl uenced outcome (32). The interventi on 
consisted of 3 sessions. The fi rst focused on providing informati on regarding the 
illness and explaining symptoms and terminology, as well as exploring the pati ents’ 
beliefs regarding it. The second session focused on these beliefs to create a plan 
to decrease future symptoms and to create a greater sense of control. In the third 
session, this plan was evaluated, and symptoms and fears concerning recovery were 
discussed. Pati ents reported fewer symptoms 3 months aft er this interventi on and 
returned to work earlier than controls.
Similar interventi ons may be benefi cial to other groups of pati ents as well, such 
as VS pati ents. It is important to realize that recently diagnosed VS pati ents in a way 
experience their illness as acute probably because they have just been diagnosed 
with a new illness. However, in another way, they experience their illness as chronic 
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perhaps because they realize that it will not be cured within a short period of ti me. 
This may call for a diﬀ erent approach to the VS pati ent than to the pati ent who has 
acute myocardial infarcti on when implementi ng a change in ilness percepti ons.
Because of the previously observed relati onship between QoL and coping, that is, 
seeking social support, it may be expected that sti mulati ng pati ents to join pati ent 
support groups and pati ent societi es may be benefi cial to VS pati ents, especially 
those lacking social support. Sharing concerns and experiences may ameliorate QoL 
and perhaps change illness percepti ons in such a way that pati ents exhibit more 
opti mism and develop more problem-focused coping and seek social support. 
Questi onnaires may be helpful to the clinician in pinpointi ng a more-than-average 
decreased QoL, adverse illness percepti ons, and subopti mal coping behavior. The 
clinician may be able to intervene and anti cipate on this decreased QoL even before 
treatment by means of adjustment of treatment proposal, and both pretreatment and 
postt reatment, by oﬀ ering extra care and att enti on when needed, for example, in the 
form of social workers. Assessing QoL via a concise questi onnaire adds signifi cantly 
to the quality of medical care. It does take a few minutes to fi ll out questi onnaires. 
However, it takes (much) more ti me to do a blood test, let alone a more invasive 
biomedical diagnosti c test, which not always adds any relevant extra knowledge. 
Finally, this study confi rms previous knowledge on diminished QoL in VS pati ents 
and adds informati on regarding illness percepti ons and coping behavior. Our study 
provides clinicians with knowledge concerning the psychological factors that possibly 
infl uence QoL and, thus, outcome in VS pati ents. With awareness regarding this 
topic, we can try to improve QoL in VS pati ents. 
Conclusion
QoL of our sample of VS pati ents at diagnosis, measured with SF-36, is less than that 
of the general populati on, and for most subscales, also less than the QoL of pati ents 
with head and neck cancer, deaf pati ents, pati ents with BPH, and pati ents with COPD. 
Illness percepti ons are in between those of pati ents with acute and chronic pain and 
slightly more positi ve than those of pati ents with head and neck cancer and COPD.
VS pati ents disti nguish themselves from the general Dutch populati on by 
being less acti ve in their coping behavior. Pati ents undergoing bone marrow 
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transplantati on show slightly more acti ve behavior, whereas pati ents who have 
chronic pain show signifi cantly less acti ve coping behavior. 
Because illness percepti ons and coping, but especially QoL in VS pati ents, 
are not as good as reference values, it is worth investi gati ng possibiliti es for 
improvement. It is important for all those taking care of VS pati ents, both clinically 
and nonclinically, to be aware of this decrease in QoL at diagnosis. According 
to the study of Petrie et al. (32), we may be able to improve outcome by an 
interventi on in the fi eld of illness percepti ons. Keeping this in mind, it would be 
valuable to investi gate the role of illness percepti ons, coping, and symptoms on 
QoL in VS pati ents in a future study to evaluate the possibiliti es for improvement 
of QoL in this group of pati ents.
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Abstract
Objecti ve: To determine the natural history and long term quality of life outcome 
following conservati ve treatment for vesti bular schwannoma. 
Study Design: Prospecti ve study conducted in a university-based terti ary referral 
centre.
Pati ents: A total of 70 vesti bular schwannoma pati ents who were initi ally included in 
the wait and scan protocol between January 2002 and December 2003 were followed 
with a mean observati on ti me of 43 months. All pati ents had small- or medium-sized 
tumors when they were included in the protocol. Quality of life was measured at 
diagnosis and at the end of follow-up in those pati ents who were sti ll conservati vely 
treated using the SF-36. The study group was characterized by non-growing small 
tumors and relati vely stable symptoms over ti me.
Main outcome measures: Clinical, audiometric, radiological and quality of life results. 
Results: In 44 pati ents (63%), growth of the tumor was not observed, and 25 (36%) 
tumors did grow. Of the 70 included pati ents, 27 pati ents (39%) ulti mately required 
treatment. Forty-one pati ents (59%) were sti ll conservati vely treated at the end of 
follow-up (mean, 47 ± 16 mo). Hearing was preserved in 16 (57%) of the 28 pati ents 
with useful hearing at diagnosis. At the end of follow-up, SF-36 scores were only 
slightly deteriorated for almost all subscales when compared to scores at diagnosis; 
however, diﬀ erences were stati sti cally not signifi cant (p > 0.05). There was no 
signifi cant correlati on between the presence of cochleovesti bular symptoms and 
quality of life scores (p > 0.05).
Conclusion: Conservati ve observati on of small vesti bular schwannomas may be 
regarded as a reasonable management opti on because the majority of these tumors 
do not grow during an initi al period of observati on. Conservati ve treatment of this 
subset of pati ents with small, non-growing tumors does not signifi cantly aﬀ ect life 
functi oning, as refl ected in SF-36 survey data. However, hearing loss did progress in 
this populati on. Thus, pati ents should be counseled regarding this risk and generic 
quality of life measures such as the SF-36 should be used with cauti on in future 
assessments. This study emphasizes the importance of combining generic and 
disease-specifi c quality of life measures in future studies of protocols of vesti bular 
schwannoma management.
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Introducti on
Traditi onally, treatment of vesti bular schwannomas consists of microsurgical 
excision or stereotacti c irradiati on therapy. However, conservati ve management has 
increasingly become a treatment opti on in appropriate cases (1-5). The criteria used 
for recommendati on of wait and scan include the pati ent’s age and health status, 
tumor size and locati on, hearing status, and the pati ent’s preference. The rati onale 
for a wait and scan policy in vesti bular schwannoma (VS) is the indolent growth 
patt ern and stati c presentati on in most cases (6,7). Improved magneti c resonance 
imaging (MRI) techniques now allow for an early diagnosis and exact measurement 
of growth, which has led to an increased number of pati ents with small and minimally 
symptomati c tumors suitable for conservati ve treatment. In a recent meta-analysis 
on conservati ve management, it was stated that wait and scan may be regarded as a 
safe approach for selected pati ents because most of the observed tumors (57%) did 
not grow, and only a minority of pati ents (20%) required treatment (i.e., microsurgery 
or stereotacti c irradiati on). However, the authors also concluded that there is a lack 
of prospecti vely designed studies with a clinical, radiologic, and audiometric follow-
up beyond 3 years (8). 
Over the past decades, quality of life (QoL) has increasingly become an important 
outcome measure for both pati ents and clinicians when discussing treatment opti ons 
for VS. Several arti cles have been published on the pati ents’ perspecti ve of what 
consti tutes a (radio)surgical success (9-14). It is now well recognized that microsurgical 
treatment of VS aﬀ ects the pati ents’ QoL signifi cantly, and a trend toward more 
inferior QoL has been reported aft er stereotacti c irradiati on or radiosurgery. However, 
pati ent outcomes aft er conservati ve treatment have been scarcely described, and 
reports are oft en limited by the retrospecti ve design or poorly described reference 
data (13,15). 
A wait and scan policy implies that VS pati ents have to undergo periodic MRI and 
clinical evaluati on to assess growth or progression of symptoms at least for several 
years aft er the diagnosis. In our opinion, to have a VS can therefore be considered 
as a chronic illness, which may be life-threatening in some cases. So far, it remains 
unclear how pati ents experience this kind of conservati ve approach for intracranial 
tumors such as VS; the eﬀ ects of this treatment on QoL over ti me also remain to be 
elucidated. In this study, therefore, our fi rst aim was to determine the natural course 
of VS and to identi fy and follow those pati ents who did not require treatment over 
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ti me. Second, QoL and possible correlati ons with cochleovesti bular symptoms were 
prospecti vely studied with a follow-up of almost 4 years.
Materials and Methods
Pati ents
Between January 2002 and December 2003, 82 newly diagnosed VS pati ents were 
included in our wait and scan protocol. Inclusion criteria for conservati ve management 
were minimal symptoms, small- or medium-sized tumors, advanced age, poor general 
health, or pati ent preference. Pati ents were excluded from the study if they had 
neurofi bromatosis type 2 (n = 1), previous surgical, or radiosurgical therapy (n = 5). 
Pati ents who were lost to follow-up (n = 2) or had less than 2 MRIs (n = 4) were also 
excluded. This resulted in 70 pati ents (29 men and 41 women) who were included 
in this study; they were followed unti l April 2008. The clinical data were obtained 
from the pati ents’ clinical charts and our prospecti vely generated VS database (16). 
Pati ents remained included in the wait and scan protocol if surgical or radiosurgical 
interventi on was not required. The decision for conversion to acti ve treatment was 
based on the following criteria: signifi cant tumor progression on repeated MRI, 
objecti vely quanti fi ed hearing deteriorati on, or the pati ent’s preference for acti ve 
treatment (e.g., in case of increase in cochleovesti bular symptoms). In case of the 
need for surgical treatment, the surgical approach was based on the pati ent’s hearing 
and the surgeon’s preference for an approach technique. Facial nerve outcome was 
assessed according to the House-Brackmann classifi cati on (Grades I to VI) (17). In 
case of radiosurgical interventi on, pati ents received stereotacti c irradiati on or 
radiosurgery.
Neuroradiologic Assessment 
All pati ents underwent periodic gadolinium-enhanced MRI to determine tumor 
size or growth. In our clinic, imaging is generally performed at 12-month intervals 
within the fi rst 4 years aft er the diagnosis. The scanning interval aft er this period was 
dictated by the clinical status of the pati ent or the pati ents’ preference regarding 
the durati on of the interval, tumor growth rate, or size of the tumor. The durati on 
of follow-up was defi ned as the interval between the fi rst and last MRI within 
the observati on period. Tumor size was determined using the guidelines of the 
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American Academy of Otolaryngology Head and Neck Surgery (AAO-HNS) (18). The 
extracanalicular component of the tumor was determined as follows: the maximum 
tumor diameter was measured on T1-weighted axial MRI images with gadolinium 
enhancement. The measurement was calculated parallel to the petrous bone and 
perpendicular to it. The size of tumors limited to the internal auditory canal was 
calculated on T1-weighted axial MRI images with gadolinium enhancement, and the 
total length of the tumor along the axis of the internal auditory canal from the porus 
to the fundus was measured.
Tumor growth or shrinkage was considered signifi cant in case of an increase or 
decrease of 2 mm or more in comparison with the previous MRI scan, as proposed 
by Fucci et al. (3) and Stangerup et al. (19). The growth rate was calculated by dividing 
the diﬀ erence in tumor size between the initi al and the last available MRI scan by 
the overall follow-up ti me (in months) and by multi plying the obtained fi gure by 12.
Audiometric Assessment
Audiometric assessments were periodically performed during conservati ve 
management. In this study, the audiometric results were recorded at diagnosis and 
at last clinical evaluati on. The pure-tone average (PTA) was calculated as the mean 
sum of 0.5, 1, 2, and 4 kHz hearing thresholds. Speech discriminati on scores (SDSs) 
were obtained in quiet conditi ons using word list scoring by phonemes and recorded 
according to the guidelines of the AAO-HNS (18). Hearing was classifi ed (according 
to AAO-HNS): Class A, PTA less than or equal to 30 and SDS greater than or equal to 
70%; class B, PTA less than or equal to 50 dB and SDS greater than or equal to 50%; 
class C, PTA greater than 50 dB and SDS less than 50%; and class D, SDS less than 50%. 
QoL Assessment
The SF-36 was used to measure QoL during the observati on period. All the included 
pati ents fi lled out the SF-36 questi onnaire at the ti me of their diagnosis, and the 
pati ents who were sti ll included in the wait and scan protocol at the end of the 
observati on period fi lled out the same questi onnaire again (April 2008). The mean 
scores at ti me of diagnosis and at the end of the observati on period were then 
compared with each other. Furthermore, relati onships between QoL scores and 
cochleovesti bular symptoms or change in symptoms were analyzed. The SF-36 is 
widely used and validated as a generic outcome measure in a variety of diseases 
throughout diﬀ erent pati ent populati ons (20, 21). It has also been extensively used 
50 | Chapter 3
in measuring QoL in VS pati ents (9-16). The SF-36 assesses QoL in the following 8 
domains: physical functi oning, social functi oning, physical role functi oning, emoti onal 
role functi oning, mental health, vitality, bodily pain, and general health. For each 
domain, there is a series of itemized questi ons that are scored. Each score is coded, 
summed, and presented on a scale of 0 to 100, where 0 implies the worst possible 
health status and 100 the best possible (22). 
Stati sti cal Analysis
Stati sical analysis was performed using SPSS version 14.0 for Windows. The 2-tailed 
independent t-test was used for comparison between groups and the paired t-test 
for comparison within groups with a 95% level of signifi cance (p < 0.05). Correlati ons 
between variables were analyzed using the Pearson correlati on coeﬃ  cient. 
Nonparametric equivalents were used in case of not normally distributed data.
Results 
Clinical Results
The pati ents’ characteristi cs are shown in Table 1. The overall average tumor size at 
presentati on was 10 mm (range, 2-27 mm). There were 30 intracanalicular tumors 
and 40 extrameatal tumors (mean, 7 ± 2 mm and 12 ± 5 mm, respecti vely), and 
groups did not diﬀ er signifi cantly in age or sex (p = 0.4 and p = 0.6, respecti vely). 
The presenti ng symptoms are shown in Table 2. Unilateral hearing loss, ti nnitus, 
and balance problems were the 3 most common presenti ng symptoms. For most 
of the pati ents (64%), the durati on of their (cochleovesti bular) symptoms was 6 to 
24 months unti l diagnosis. There was no signifi cant correlati on between presenti ng 
symptoms and initi al tumor size or intracanalicular or extracanalicular tumors 
(p = 0.4). 
Tumor Growth
In 44 (63%) pati ents, no tumor growth was observed during the enti re observati on 
period. In 1 (1%) pati ent, tumor shrinkage occurred. At a mean follow-up of 32 
months (range, 11-67 mo), tumor growth occurred in 25 pati ents (36%). Within the 
group of extrameatal tumors (n = 40), 22 tumors (55%) did not grow, whereas 17 
tumors (43%) did grow. In 1 tumor (2%) within the extrameatal tumor group, tumor 
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shrinkage was observed aft er 36 months of follow-up. In 8 tumors (27%) within the 
intracanalicular group (n = 30), tumor growth was observed, and the remaining 22 
tumors (73%) did not show tumor growth. Among the extrameatal tumors, a larger 
number of tumors showed enlargement when compared with the intracanalicular 
tumors. However, this diﬀ erence was stati sti cally not signifi cant (p = 0.3). The mean 
growth rate of the growing tumors (both intracanalicular and extrameatal) was 
1.5 mm/yr, and the overall growth rate was 0.45 mm/yr. There was no signifi cant 
relati on between pati ent’s age, sex, initi al tumor size, or presenti ng symptoms and 
growth rate (all p > 0.05). Tumor growth rate also did not signifi cantly diﬀ er between 
intracanalicular or extrameatal tumors (p = 0.1). 
Table 1. Pati ent characteristi cs (n = 70).
No. of pati ents 70
Age at diagnosis, yr 60 (35-82)
Male/female 29: 41
Follow-up, mo 40 (11-73)
Initi al tumor size, mm 10 (2-27)
Table 2. Presenti ng symptoms (n = 70).
Symptom No. of pati ents (%)
Unilateral hearing loss 69 (99)
Tinnitus 38 (54)
Dizziness 31 (44)
Verti go 18 (26)
Other*  3 (4)
*Trigeminal neuralgia, facial nerve paralysis.
Treatment Group (Failure of Conservati ve Management)
A total of 27 pati ents failed (39%) conservati ve management during the observati on 
period aft er a mean follow-up of 31 months (median, 30 mo; range, 11-67 mo) 
because in these pati ents, microsurgery or radiosurgery was required. Pati ents 
were followed for an average of 11 months postsurgery (median, 11 mo; range, 
8-12 mo). Nineteen pati ents (76%) underwent microsurgery and 5 pati ents (30%) 
received radiosurgery because of tumor growth. One pati ent (4%) with tumor 
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growth remained included in the wait and scan protocol (because of inconsistent 
tumor growth). Three pati ents without tumor growth, but with a signifi cant increase 
in cochleovesti bular symptoms during the observati on period, also underwent 
surgical treatment. Two of these pati ents were operated via the translabyrinthine 
(TL) approach, and 1 pati ent underwent successful hearing preservati on surgery via 
the middle fossa (MF) approach. The surgical outcome of these pati ents is presented 
in Table 3. Facial nerve outcome was favorable (House-Brackmann Grades I and II) 
in all operated pati ents, and there were no major postoperati ve complicati ons. Two 
pati ents died during follow-up because of medical reasons not related to VS.
Table 3. Surgical outcomes of 22 primarily conservati vely treated pati ents.
Pati ent Surgical 
approach
Hearing functi on 
at diagnosis*
Preoperati ve 
hearing functi on 
preoperati vely* 
Postoperati ve 
hearing functi on 
postoperati vely*
1. TL D D D
2. TL D D D
3. TL D D D
4. TL D D D
5. TL D D D
6. TL C C D
7. TL C C D
8. TL C C D
9. TL C C D
10. TL C C D
11. TL C C D
12. TL B D D
13. TL B B D
14. TL B C D
15. TL B B D
16. TL B D D
17. TL C D D
18. TL B C D
19. TL A B D
20. TL A D D
21. TL A B D
22. MF A A A
* American Academy of Otolaryngology Head and Neck Surgery hearing classifi cati on (18). TL indicates 
translabyrinthine surgery; MF, middle fossa surgery.
Conservati ve treatment of vesti bular schwannoma: a follow-up study on clinical and quality of life outcome | 53 
Nontreatment Group (Nonfailure of Conservati ve Treatment)
At the end of the observati onal period, a total of 41 pati ents (59%) were sti ll included 
in the wait and scan protocol (mean, 47 ± 16 mo; range, 12-73 mo). The pati ents’ 
characteristi cs are presented in Table 4. The overall average tumor size was 10 mm 
(range, 2-27 mm). There were 20 intracanalicular tumors and 21 extrameatal tumors 
(mean, 7 ± 3 mm and 14 ± 6 mm, respecti vely), and groups did not signifi cantly 
diﬀ er in age or sex (p = 0.2 and p = 0.4, respecti vely). The presenti ng symptoms in 
these pati ents and subsequent symptoms at the end of the observati on period are 
presented in Table 5. Of the presenti ng symptoms, hearing loss worsened in 20 (49%) 
of the 41 pati ents. Pati ents presenti ng with balance problems reported improvement 
of dizziness and verti go in 5 (26%) of the 19 pati ents and in 5 (42%) of the 12 pati ents, 
respecti vely. Dizziness and verti go worsened in 3 (16%) of the 19 pati ents and in 
2 (17%) of the 12 pati ents, respecti vely. Symptoms in 2 pati ents presenti ng with a 
trigeminal neuralgia and 1 pati ent with a mild facial nerve paralysis did not change. 
There was no signifi cant correlati on between presenti ng symptoms or change in 
presenti ng symptoms and initi al tumor size or intracanalicular or extracanalicular 
tumors (all p > 0.05). The score distributi on on the SF-36 dimensions is listed in Table 
6. At follow-up, the SF-36 scores of the 41 pati ents had slightly deteriorated compared 
with the scores at baseline some 4 years earlier except for social functi oning, which 
was slightly improved. However, the SF-36 scores at follow-up did not signifi cantly 
diﬀ er when compared with scores at baseline (all p > 0.05). Baseline and follow-
up SF-36 scores did not correlate signifi cantly with cochleovesti bular symptoms or 
tumor size (all p > 0.05). 
Table 4. Pati ent characteristi cs for the nontreatment group (n = 41).
No. of pati ents 41
Age at diagnosis, yr 63 (40-79)
Male/ female 16:25
Follow up, mo 47 (12-73)
Initi al tumorsize, mm 10 (2-27)
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Table 5. Presenti ng symptoms and change at the end of observati on (n = 41).
Symptom No. of pati ents (%) report-
ing symptoms at baseline
No. of pati ents reporti ng symptoms at 
follow-up
No change Bett er Worse
Unilateral hearing loss 41 (100) 21 0 20
Tinnitus 26 (63) 24 0  2
Dizziness 19 (46) 11 5  3
Verti go 12 (29)  5 5  2
Other*  3 (7)  3 0  0
*Trigeminal neuralgia, facial nerve paralysis.
Table 6. Quality of life scores of the conservati vely treated pati ents (n = 41).
Short Form-36 scales
At diagnosis End of observati on
Mean SD Mean SD
PF  81.0 23.9 80.3 23.3
SF  74.3* 28.3 77.1* 22.7
RP  73.6 39.7 72.6 40.3
RE  82.4 31.0 78.9 33.1
MH  70.0* 15.7 69.4* 16.5
VT  66.8 15.8 63.6 18.8
BP  86.3* 18.8 84.8 18.3
GH  57.4* 18.3 56.6* 20.6
PF indicates physical functi oning; SF, social functi oning; RP, role-physical functi oning; RE, role-emoti onal 
functi oning; MH, mental health; VT, vitality; BP, bodily pain; GH, general health; SD, standard deviati on; 
* p < 0.05. 
Audiometric Results
At their diagnosis, 33 pati ents (47%) presented with useful hearing on the tumor ear 
(Classes A and B of the AAO-HNS classifi cati on), whereas 37 pati ents (53%) had no 
serviceable hearing on the tumor ear (Classes C and D of the AAO-HNS classifi cati on) 
(18). In 5 (15%) of the 33 pati ents with useful hearing, follow-up audiometry was 
not available. During the observati on period, 12 pati ents (43%) of the remaining 
28 pati ents within the useful hearing group lost their (useful) hearing, and in 16 
pati ents (57%), useful hearing was maintained. Of the 12 pati ents who lost their 
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useful hearing, 4 pati ents lost their hearing because of TL surgery resulti ng in 
permanent hearing loss in the tumor ear. A total of 5 pati ents who underwent TL 
surgery during the observati onal period lost their useful hearing before the surgery 
was performed (Table 3). In the remaining 3 pati ents, useful hearing was lost during 
the observati onal period. No signifi cant diﬀ erence was found in loss of useful 
hearing between intracanalicular and extrameatal tumors (p = 0.2). Nearly half of 
the pati ents with useful hearing and with a growing tumor lost their hearing because 
of the TL surgery. A correlati on between tumor growth and hearing loss could not 
be adequately interpreted because of the bias caused by the inevitable hearing loss 
aft er TL surgery. 
Discussion
This study reported on 1 of the few follow-up studies in VS pati ents, with a set of 
outcome variables that encompasses clinical and QoL data. We described the natural 
course of VS in a prospecti ve manner and with a focus on the long term QoL in those 
pati ents who were sti ll conservati vely treated aft er almost 4 years of observati on. 
During the observati onal period, the vesti bular schwannomas seemed to be 
nongrowing in most pati ents (63%). This fi nding is in line with earlier studies in 
which absence of growth has been reported in 40% to 76% of cases (1-6,23-26). 
Furthermore, these results are underlined by the data of a recent meta-analysis 
performed by Smouha et al. (8); they found that in 1,345 VS pati ents, 57% of tumors 
were nongrowing, whereas 43% showed positi ve growth during a mean follow-up 
of 3.2 years. The observed nongrowth rate of 57% was likely to be overesti mated 
according to the authors because of the relati vely short durati on of follow-up. 
Nonetheless, several studies, including our study with longer follow-up periods 
ranging from 3 to 7 years, sti ll report high nongrowing tumor rates (24-26). We also 
observed tumor involuti on during the observati onal period in 1% of cases, which 
is also in line with reported tumor regression rates. The observed spontaneous 
involuti on of vesti bular schwannomas may be explained by tumor necrosis caused by 
intratumoral thrombosis and may be part of normal involuti on of tumors that have 
reached their maximum growing potenti al (27). The growth patt erns of VS may vary 
from spontaneous involuti on to rapid growth, and unfortunately, not many clinical or 
radiologic factors predicti ng tumor growth have been found so far. Intracanalicular 
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tumors are thought to display less growth than extracanalicular tumors, and younger 
age is associated with more rapid growth and the presence of intratumoral cysts 
(25,26,28). Although we observed an increased number of growing tumors in the 
extracanalicular tumor group compared with intracanalicular tumors, this diﬀ erence 
was not stati sti cally diﬀ erent. Other pati ent or tumor factors (i.e., age, presenti ng 
symptoms, tumor size) were also not signifi cantly related to observed growth. 
In the current study, failure was defi ned as conversion from wait and scan to acti ve 
treatment, which occurred in 39% of pati ents. Various studies report a percentage of 
failure between 0 and 50% (26). As in most of these studies, our decision for defi niti ve 
treatment was mostly based on signifi cant tumor growth observed on MRI. However, 
in our study, not all pati ents with tumor growth received treatment. For instance, 
in 1 pati ent, the inconsistent tumor growth was observed for several years, and 
there was no increase of symptoms or deteriorated QoL. In this pati ent, therefore, 
treatment was successfully postponed. In 3 pati ents, however, a signifi cant increase 
in cochleovesti bular symptoms occurred, and fi nally, pati ents preferred to undergo 
microsurgical treatment. One of these pati ents underwent hearing preservati on 
surgery using the MF approach, and useful hearing was postoperati vely maintained 
(Table 3). The other 2 pati ents underwent TL surgery and subsequent vesti bular 
neurectomy because of the disabling character of their verti go. Postoperati vely, 
there were no major complicati ons, and facial nerve functi on was favorable for all 
22 operated pati ents. 
Consistent data concerning hearing loss or other cochleovesti bular symptoms 
aft er conservati ve treatment is sti ll scarcely found (8). We found that useful hearing 
was maintained in 57% of pati ents aft er almost 4 years of follow-up. However, one 
should be cauti ous while interpreti ng these data because in some pati ents, recent 
audiometric data were not available (15%). Furthermore, a relati onship between 
tumor progression and hearing loss could not be established because nearly half of 
the pati ents with useful hearing and with a growing tumor lost their hearing because 
of the TL surgery. Other authors have reported on hearing loss in 50 to 67% of cases 
aft er conservati ve treatment and regardless of tumor progression (29). Studies 
concerning hearing preservati on surgery have claimed some degree of preserved 
hearing in 35 to 60% of cases, and similar results are reported aft er radiosurgery 
(30). When considering these results, hearing preservati on, therefore, could sti ll be 
a matt er of debate when discussing treatment opti ons for small- and medium-sized 
vesti bular schwannomas.
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VS may be regarded as a chronic illness, which causes discomfort and may 
lead to unilateral hearing loss, ti nnitus, or balance problems. Moreover, pati ents 
treated conservati vely have to undergo periodic radiologic, audiometric, and clinical 
assessment for a prolonged period aft er their diagnosis. Therefore, informati on 
regarding QoL during the course of conservati ve treatment is of great importance 
for this group of pati ents. Of the 70 pati ents initi ally included in the wait and scan 
protocol, 41 pati ents (59%) were successfully treated with a mean follow-up of 47 
months. As expected from earlier studies, conservati ve treatment did not signifi cantly 
aﬀ ect our pati ents’ QoL (1-5,13, 15,25,26,31). We performed an observati onal study in a 
populati on of pati ents with small, nongrowing tumors for which symptoms were likely 
to remain stable over ti me. Furthermore, QoL scores seemed not to be infl uenced by 
the presenti ng symptoms or change in symptoms during the follow-up period. Of the 
main symptoms, deteriorati on of hearing loss was reported mostly by the pati ents, 
but the loss of hearing did not seem to aﬀ ect QoL. A possible explanati on might 
be the gradual character of the hearing loss or the fact that most pati ents already 
had nonserviceable hearing at diagnosis (21 of the 41 pati ents). Almost one third of 
pati ents with balance problems at diagnosis reported improvement over ti me, which 
may be explained by the gradual dysfuncti on of the vesti bular nerve from the VS 
accompanied by vesti bular compensati on in the central nervous system. Two pati ents 
reported that their verti ginous complaints had worsened, but without signifi cantly 
aﬀ ecti ng their QoL, and therefore, they did not receive treatment yet. However, 
it is now well recognized that the SF-36, a widely used generic questi onnaire, has 
limitati ons with respect to otolaryngologic interventi ons or auditory and vesti bular 
functi oning (32,33). In our opinion, the interpretati on of QoL results should therefore 
be done with cauti on. When compared with other published results from our center 
in which QoL was measured in VS pati ents before treatment decision or proposal, 
our pati ents had bett er QoL scores (16). Again, this illustrates the pati ent selecti on in 
our sample. 
Although this study was conducted using a prospecti ve design, there are a 
number of limitati ons to this study of which some are already menti oned earlier. The 
interpretati on of our QoL results is hampered by lack of data of the treated pati ents. 
We have not investi gated QoL in these pati ents because of the relati vely small 
pati ent subgroups (microsurgery and radiosurgery; n = 22 and n = 5, respecti vely). 
Pati ents were followed-up for almost 1 year postsurgery. We are aware that these 
data are preliminary, and longer and more profound follow-up is needed of the enti re 
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cohort. Furthermore, with regard to the use of the SF-36, it should have been more 
preferable to combine generic with disease-specifi c measures of QoL. However, 
unti l now, no validated questi onnaire is available for assessing VS-specifi c QoL. We 
have therefore, in our opinion, used the best methods available. We acknowledge 
the importance of combining generic and disease-specifi c QoL measures for future 
research projects. The results of this study may be valuable for counseling pati ents 
with small- or medium-sized vesti bular schwannomas.
Conclusion
Conservati ve management is increasingly adopted as an initi al treatment opti on for 
VS. As shown in previous reports, our study shows that conservati ve management 
of small tumors is a reasonable opti on because most tumors do not grow. Useful 
hearing was preserved in half of the pati ents, which is in line with existi ng literature. 
Conservati ve treatment does not seem to worsen the pati ents’ QoL over ti me. 
However, in this study, pati ents with nongrowing small tumors and with stable 
cochleovesti bular symptoms were prospecti vely followed. Of the symptoms, hearing 
loss deteriorated most frequently during follow-up, and QoL does not seem to 
meaningfully deteriorate due to hearing changes in the involved ear. However, it 
should be taken into account that the SF-36 has its limitati ons with regard to assessing 
QoL in otolaryngologic interventi ons and sensiti vity to symptoms such as hearing loss 
or balance problems. It should therefore have been preferable to combine generic 
with disease-specifi c measures of QoL. 
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Abstract
Objecti ve: To assess quality of life and clinical outcome in vesti bular schwannoma 
pati ents aft er radiosurgery with marginal tumor doses of 12 Gy.
Study Design: Retrospecti ve study conducted in a university-based referral centre.
Pati ents and Methods: Seventy-two consecuti ve, newly-diagnosed pati ents with a 
solitary vesti bular schwannoma underwent linear accelerator-based radiosurgery 
between 2001 and 2007, all with marginal tumor doses of 1 x 12 Gy prescribed to the 
80% isodose-line. A total of 66 pati ents were included in the study and 64 pati ents 
(97%) fi lled out the SF-36. The SF-36 scores of the pati ents were compared with SF-
36 scores of healthy controls. Local tumor control and symptoms were also studied. 
The median follow up between treatment and quality of life assessment measured 
34 months (mean, 35 mo; range, 3-78 mo). The median imaging follow-up was 31 
months (mean, 34 mo; range, 4-64 mo). 
Main outcome measures: Quality of life and clinical results.
Results: The median tumor diameter was 17 mm (mean, 17 mm; range, 4-28 mm). 
The clinical tumor control rate was 100% aft er a median follow-up of 31 months 
(mean, 34 mo; range, 4-64 mo). The imaging control rate was 98%. None of the 
pati ents had serviceable hearing before the radiosurgery. Dizziness and ti nnitus were 
present in 45 (70%) and 46 (72%) pati ents before treatment, respecti vely. None of 
the pati ents developed dizziness or ti nnitus aft er treatment, but dizziness worsened 
in 2 (3%) and ti nnitus in 3 (5%) pati ents. Facial nerve and trigeminal symptoms 
developed aft er treatment in 2 (3%) and 4 (6%) pati ents, respecti vely. In one pati ent 
(2%) hydrocephalus occurred. The SF-36 scores for social functi oning and general 
health were stati sti cally signifi cantly lower when compared to healthy controls (p = 
0.01 and p = 0.001, respecti vely). There was no signifi cant correlati on of the SF-36 
scores and tumor size, dizziness, facial or trigeminal nerve symptoms or co-morbidity. 
Tinnitus inversely correlated with physical-role functi oning (p = 0.01). 
Conclusion: Vesti bular schwannoma pati ents experience impaired quality of life aft er 
radiosurgery when compared to healthy controls. However, radiosurgical treatment 
for vesti bular schwannoma oﬀ ers good tumor control and favorable clinical outcome 
similar to earlier reports. There is no signifi cant correlati on between quality of life 
outcome and disease-related symptoms, tumor size or comorbidity.
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Introducti on
Over the past decades, radiosurgery has become a well-established treatment for 
vesti bular schwannoma (VS) (1-7). The two main goals of treatment are long term 
tumor control and preservati on of quality of life (QoL), including neurological 
functi ons. Recent studies have reported long term clinical tumor control rates 
up to 97-99% with low marginal doses (12-14 Gy) (3-5). Despite these advances, 
radiosurgical treatment of vesti bular schwannoma may induce or worsen complaints 
such as hearing loss, ti nnitus, facial nerve dysfuncti on, facial pain and dysbalance. 
Another sequelae of treatment is hydrocephalus, which may require a ventriculo-
peritoneal shunt (8,9).
In VS literature, the frequency and impact of these symptoms vary considerably, 
but an increased awareness of QoL issues has drawn more att enti on to these 
outcomes. Most radiosurgical reports, however, mainly focus on tumor control and 
objecti ve neurological defi cit. More subjecti ve eﬀ ects of radiosurgery on for instance 
ti nnitus, dizziness or balance problems are scarcely reported (3). Especially imbalance 
and verti go have shown to result in an impaired QoL (10,11). 
So far, litt le is known from the pati ents’ perspecti ve of what consti tutes a 
radiosurgical success. In order to increase knowledge of the pati ent’s percepti on of 
radiosurgical treatment of VS, we assess QoL and clinical outcome in newly-diagnosed 
pati ents with solitary VS aft er linear accelerator-based (LINAC) radiosurgery.
Materials and Methods
Pati ents
Between June 2001 and December 2007, 72 consecuti ve newly-diagnosed pati ents 
with unilateral VS underwent linear accelerator-based (LINAC), low-dose radiosurgery 
at the Erasmus University Medical Centre in Rott erdam with marginal doses of 12 Gy. 
Retrospecti ve analysis of the clinical charts showed that of the 72 pati ents, 6 pati ents 
were deceased. It were all disease unrelated deaths: four pati ents died because of 
a primary malignancy or metastasis of a malignant tumor, one pati ent died of a 
glioblastoma and one pati ent passed away as a result of old age. No pati ents were lost 
to follow up. This resulted in 66 eligible pati ents for our study. To obtain the QoL data, 
all these pati ents received a questi onnaire accompanied by a lett er informing them 
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of the purpose of the study and instructi ons on how to complete the questi onnaires. 
A total of 64 pati ents completed and returned the questi onnaire (97%). Two pati ents 
were unwilling to parti cipate and did not fi ll out the questi onnaire. The pati ent 
data were obtained from the pati ents’ clinical charts and our VS database; they are 
summarized in Table 1. The median age of the 64 pati ents was 65 years (mean, 66 
yr; range, 36-84 yr) when they fi lled out the questi onnaire. Thirty two pati ents (50%) 
were male. Follow-up was defi ned by the ti me interval between treatment and the 
most recent MRI scan and neurological examinati on. The median follow-up of the 64 
pati ents was 31 months (mean, 34 mo; range, 4-64 mo).
Table 1. Pati ent characteristi cs (n = 64).
No. of pati ents 64
Age, yr (median, range) 66 (65, 36-84)
Male/female 32:32
Follow-up, mo 34 (31, 4-64)
Initi al tumor size, mm 17 (17, 4-28)
Tumor characteristi cs
All tumor diameters were measured and volumes were calculated using the planning 
magneti c resonance imaging (MRI) scan. The median tumor diameter was 17 mm 
(mean, 17 mm; range, 4-28 mm) and the median tumor volume was 2.2 cm³ (mean, 
2.2 cm³; range, 0.1-11.4 cm³). 
Local tumor control was assessed in two ways. First, by imaging; radiological 
tumor control was defi ned as an increase in tumor diameter of less than 2 mm in 
any directi on. A 2 mm diﬀ erence seems appropriate because of the variati on in voxel 
size and scan angle/head positi on during MRI. Second, by fi nal clinical outcome; local 
control was defi ned as freedom from surgical resecti on.
Radiosurgical treatment
Pati ent immobilizati on was provided by the Brown-Robert-Wells stereotacti c 
coordinate headframe from Radionics (Radionics Inc., Burlington, MA, USA). 
Stereotacti c planning computed tomography (CT) scans were performed and 
co-registered with 1-2 mm slice thickness MRIs. The XKnife™ RT soft ware from 
Radionics was used for image fusion, contouring and planning. Tumor and organs 
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at risk delineati on was carried out on T1-weighted MRI sequences. A dose of 12 Gy 
was delivered at the 80% isodose by means of a Varian 2300 LINAC (Varian Medical 
Systems, Palo Alto, CA, USA).
Symptoms
Pretreatment and postt reatment trigeminal nerve symptoms were defi ned as 
subjecti ve or objecti ve decrease in facial sensati on or facial pain documented either 
by pati ent interview or physical examinati on. Pretreatment and postt reatment facial 
nerve symptoms were defi ned as any decrease in facial nerve functi on as documented 
by a decrease in House-Brackmann Grades (H-B Grades I-VI) (12). Guidelines of the 
AAO-HNS Committ ee on Hearing and Equilibrium were used to classify pati ents’ 
preoperati ve hearing status (13). Cochleovesti bular symptoms such as dizziness and 
ti nnitus were also recorded together with the pati ents’ comorbidity and neurological 
complicati ons.
Quality of life
The median follow-up between treatment and QoL assessment was 34 months 
(mean, 35 mo; range, 3-78 mo). QoL was measured using the SF-36, which is the 
most widely used generic questi onnaire to assess QoL and has been validated and 
proven to be a reliable instrument to measure general QoL (14). It consists of 36 
items comprising 8 subscales of QoL. These subscales are 1) physical functi oning 
and 2) social functi oning, that is, the degree of limitati ons experienced in daily life 
physically and socially, respecti vely; 3) physical role limitati ons and 4) emoti onal role 
limitati ons, that is, limitati ons in work or other daily acti viti es due to physical and 
emoti onal problems, respecti vely; 5) mental health, the degree of depression and 
anxiety; 6) vitality, the degree of energy and exhausti on; 7) bodily pain and 8) general 
health which quanti fi es the subjecti ve evaluati on of the pati ent’s own health status 
and pain. Higher scores indicate bett er perceived QoL. Data on pati ents’ responses 
were scored according to the instructi ons on scoring syntax in the SF-36 manual and 
Dutch populati on norms are available for reference (15). 
Stati sti cal analysis
Stati sti cal analysis was performed using SPSS version 14.0 for Windows. The one 
sample t-test was used for comparison between SF-36 scores of the radiosurgery 
pati ents and the healthy age matched control populati on. The independent samples 
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t-test was used for comparison between SF-36 scores of the radiosurgery pati ents 
using diﬀ erent pati ent or tumor variables. A 95% level of signifi cance (p < 0.05) 
was used. Correlati ons between SF-36 scores and pati ent- or tumor variables were 
analyzed using the Pearson correlati on coeﬃ  cient. 
Results
Clinical outcome
Tumor control is presented in Table 2. None of the 64 pati ents required a second 
treatment at a median follow-up of 31 months. The clinical tumor control rate was 
therefore 100%. In one pati ent increase of tumor diameter (2 mm) was observed on 
the fi rst post-irradiati on MRI due to tumor necrosis. A follow-up of more than 3 years 
showed no further tumor progression in this pati ent. This resulted in an imaging-
defi ned tumor control rate of 98%. 
Table 2. Tumor control aft er radiosurgery (n = 64). 
Tumor arrest (%) 33 (52)
Tumor reducti on (%) 30 (47)
Tumor progression (%)  1 (2)
Need for second treatment (%)  0 (0)
The clinical results are presented in Table 3. All 64 pati ents presented with non-
serviceable hearing on the ipsilateral ear before treatment (Class C and D according 
to the AAO-HNS classifi cati on) (13). Dizziness was present in 45 of the 64 pati ents 
(70%) before radiosurgery. Tinnitus was initi ally present in 46 pati ents (72%). 
Before radiosurgery, two pati ents (3%) had H-B Grade II paresis and fi ve pati ents 
(8%) experienced facial numbness or facial pain. As expected aft er treatment all 
the 64 pati ents retained non-serviceable hearing (Class C and D according to the 
AAO-HNS classifi cati on). Dizziness worsened in 2 pati ents (3%), and remained 
unchanged in 43 pati ents (67%). The pati ents who did not report dizziness before 
treatment (30%) did not develop dizziness aft er treatment. Tinnitus worsened in 3 
pati ents (5%) and remained unchanged in 43 pati ents (67%). The pati ents who did 
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not report ti nnitus before treatment (28%) did not develop ti nnitus symptoms aft er 
treatment. Two pati ents (3%) developed facial nerve palsy H-B Grade III at 7 and 8 
months aft er treatment. Facial nerve functi on did not deteriorate aft er treatment in 
the two pati ents with decreased facial nerve functi on prior to treatment. Trigeminal 
symptoms developed in four pati ents (6%) at 5, 6, 11, and 12 months postt reatment. 
There was no deteriorati on of symptoms in the fi ve pati ents with trigeminal 
symptoms before treatment. In one pati ent trigeminal symptoms even resolved at 
24 months aft er treatment. 
Table 3. Clinical results aft er radiosurgery (n = 64). 
Pre-existi ng 
defi cit (%)
Stable aft er 
treatment (%)
Worsened aft er 
treatment (%)
New aft er 
treatment (%)
Facial nerve  2 (3) 62 (97) - 2 (3)
Trigeminal nerve  5 (8) 60 (94)* - 4 (6)
Hydrocephalus  0 (0)  0 (0) - 1 (2)
New neoplasia - - - 0 (0)
Dizziness 45 (70) 62 (97) 2 (3) 0 (0)
Tinnitus 46 (72) 61 (95) 3 (5) 0 (0)
* in one pati ent pre-existi ng trigeminal symptoms improved and disappeared at 24 months aft er 
treatment.
One pati ent (2%) developed hydrocephalus at 4 months aft er radiosurgery, 
which was treated with a ventriculo-peritoneal drain and which resolved without 
permanent sequelae. There were 7 pati ents who suﬀ ered from pre-existi ng 
neurologic comorbidity: stroke (n = 5), meningioma (n = 1) and multi ple sclerosis (n = 
1). One pati ent was surgically and curati vely treated for a small cell lung carcinoma, 
one pati ent was curati vely irradiated for a prostate carcinoma and one pati ent was 
bound to a wheelchair due to orthopaedic problems.
Quality of life
The results of the SF-36 are presented in Table 4. The mean SF-36 scores for the 
radiosurgically treated pati ents were lower (i.e., refl ecti ng a poorer QoL) for all 
subscales except for bodily pain and physical functi oning when compared to the 
mean SF-36 scores of the controls. The SF-36 scores for the dimensions social 
functi oning and general health were stati sti cally signifi cantly lower when compared 
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to the controls (p = 0.01 and p = 0.001, respecti vely). The scores for bodily pain and 
physical functi oning did not signifi cantly diﬀ er from that of the controls (p = 0.4 
and p = 0.9) (Table 4). SF-36 scores did not signifi cantly correlate with tumor size, 
dizziness, trigeminal or facial nerve functi on, other sequelae such as hydrocephalus, 
or comorbidity (all p > 0.05). Physical-role functi oning inversely correlated with 
presence of ti nnitus (p = 0.01). 
Table 4. SF-36 scores aft er radiosurgery (n = 64).
Short Form-36 scales  Aft er treatment Healthy controls
Mean SD Mean SD
PF 73.0 27.9 66.7 26.0
SF 74.8* 25.7 83.2 23.7
RF 60.9 44.5 69.1 42.5
RE 76.7 40.4 82.9 33.8
MH 72.5 19.6 75.9 17.3
VT 63.2 25.5 64.2 22.0
BP 77.6 28.4 74.8 28.0
GH 53.6* 11.8 60.1 23.9
SD: standard deviati on; * p < 0.05.
Discussion
This study reported on the outcome aft er radiosurgical treatment for VS from both a 
QoL and clinical perspecti ve. As many other authors, we demonstrated that a marginal 
dose of 12 Gy is suﬃ  cient to control tumor growth of VS treated with radiosurgery. 
Our clinical tumor control rate was 100% aft er a follow-up of 31 months, which 
corresponded with earlier large series reporti ng control rates of 97-99% during a 
follow-up of 3-5.7 years (3-5). In our series, we found favorable facial and trigeminal 
outcome (97% and 94%, respecti vely), which is also in line with the results of the 
abovementi oned studies. Hydrocephalus occurred in one pati ent (2%) at 4 months 
post-treatment, which was treated with a ventriculo-peritoneal drain and without 
permanent sequelae. Roche et al. recently reported that newly developed post-
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radiosurgery hydrocephalus is generally of low incidence (1%) and that radiosurgery 
does not decompensate the majority of preexisti ng radiological hydrocephalus (8). 
Dizziness and ti nnitus were present in most of our pati ents before treatment, 
which was in line with other rates varying between 40-60% and 63-75%, respecti vely 
(16). Aft er treatment dizziness and ti nnitus worsened in only a fracti on of our pati ents, 
and there were no pati ents reporti ng new dizziness or ti nnitus. As reported earlier, 
dizziness may have serious impact on QoL (10). In this study, however, dizziness did 
not aﬀ ect QoL outcomes. Development of ti nnitus aft er VS treatment is generally 
thought to be unpredictable, but a slight overall increase has been reported. We 
found a signifi cant inverse correlati on between ti nnitus and physical daily tasks. This 
outcome was somewhat surprising, because oft en pati ents with ti nnitus experience 
emoti onal disability instead of physical disability.
We observed that social functi oning and general health domains of our treated 
pati ents were signifi cantly aﬀ ected compared to the control sample. For the other 
6 QoL domains, no signifi cant diﬀ erence was observed. Pati ents with trigeminal 
symptoms did not have signifi cantly lower pain scores when compared to other 
pati ents or the healthy control sample. The 4 pati ents (2 post-radiosurgery) with 
H-B Grades II-III did have reduced scores on social and physical functi oning domains; 
however, this observati on failed to reach stati sti cal signifi cance. 
A possible explanati on for the abovementi oned results might be that most of the 
symptoms were already present in most pati ents even before treatment and that 
pati ents adjusted to symptoms over ti me. This phenomenon is known as response 
shift  (17). 
It is now well recognized that microsurgical treatment may have a strong 
impact on the pati ents’ QoL (18,19). In additi on, stability in QoL has been reported 
following conservati ve treatment (20,21). We are aware of 5 studies reporti ng on QoL 
following radiosurgery (Table 5). Pollock et al. fi rst described functi onal outcomes 
aft er radiosurgery and microsurgery. More recently, they prospecti vely compared 
QoL outcomes between these treatment modaliti es. They concluded that QoL was 
bett er aft er radiosurgery when compared to microsurgery using validated QoL 
questi onnaires (22,23). Van Roijen et al. also investi gated QoL for both modaliti es 
and emphasized that radiosurgery was more cost-eﬀ ecti ve than microsurgery 
(24). A recent study by Régis et al. described more favorable long term outcomes 
aft er radiosurgery regarding postt reatment complicati ons and hospital stay using 
a custom made QoL questi onnaire. Furthermore, they also found that most 
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microsurgically treated pati ents experienced signifi cantly more psychobehavioral 
problems such as ti redness, depression and anxiety compared to radiosurgically 
treated pati ents. However, there was no signifi cant diﬀ erence between treatment 
modaliti es regarding ti nnitus, verti go or imbalance (25). Myrseth et al. used the SF-36 
and found that general QoL, facial nerve functi on and complicati ons rates were all 
signifi cantly in favor of radiosurgery when compared to microsurgery. However, QoL 
of both groups was reduced when compared to the healthy controls. In additi on, 
no clear relati onship was found between QoL and facial nerve functi on, tumor size 
or cochleo-vesti bular symptoms (26). Sandooram et al. recently investi gated QoL 
following radiosurgery, microsurgery and conservati ve management for vesti bular 
schwannoma using the Glasgow Benefi t Inventory (GBI). They found poorer QoL aft er 
microsurgery when compared to radiosurgery (27). From these studies it appears that 
QoL aft er radiosurgery is generally bett er when compared to microsurgery. However, 
when compared to the control populati ons, impaired QoL sti ll exists for both the 
treatment modaliti es.
We acknowledge that the retrospecti ve design is a limitati on of the study. By 
using this kind of approach, it remains unclear whether the QoL outcome is aﬀ ected 
by either the radiosurgery or by suﬀ ering from the tumor itself. Sti ll, there is evidence 
to suggest that retrospecti ve measurement of QoL is at least as clinically relevant 
and scienti fi cally sound as prospecti ve assessment (28). However, when compared to 
other published results from our center, in which QoL was measured in a sample of 
untreated VS pati ents, our radiosurgically treated pati ents displayed improved QoL 
(29). From this point of view, it appears that QoL was positi vely infl uenced by the 
radiosurgery and the QoL impairment may probably be caused by suﬀ ering from the 
disease itself. A possible explanati on might be that the radiosurgically treated VS 
pati ents experienced their illness as being controlled without serious morbidity. In 
contrast, the untreated pati ents did not receive treatment yet.
Another limitati on of the study might be the use of a generic questi onnaire (SF-
36) for QoL assessment. It would have been more preferable to combine generic with 
disease-specifi c QoL measures. Unti l now no validated questi onnaire is available for 
assessing VS-specifi c QoL. This implies that developing a VS-specifi c QoL questi onnaire 
for this specifi c category of pati ents is one research implicati on of our study. 
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Conclusion
Radiosurgery has become a well-established treatment opti on for VS. Previous 
studies have reported long term clinical tumor control rates up to 99% and favorable 
cranial nerve outcome with low marginal doses. Our study also shows that low dose 
radiosurgery for VS oﬀ ered good tumor control and comparable clinical outcome. We 
found that QoL aft er treatment was impaired when compared to the age-matched 
healthy controls, which is also in line with existi ng literature. There was no signifi cant 
correlati on between the QoL outcome and disease-related symptoms, tumor size or 
comorbidity. 
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Abstract
Objecti ve: To determine the impact of translabyrinthine surgery on quality of life in 
vesti bular schwannoma pati ents with rotatory verti go.
Study design: Prospecti ve study in 18 vesti bular schwannoma pati ents.
Setti  ng: The study was conducted in a multi specialty terti ary care clinic. 
Parti cipants: All 18 pati ents had a unilateral intracanalicular vesti bular schwannoma, 
without serviceable hearing in the aﬀ ected ear and severely handicapped by att acks 
of rotatory verti go and constant dizziness. Despite an initi al conservati ve treatment, 
extensive vesti bular rehabilitati on exercises, translabyrinthine surgery was performed 
because of the disabling character of the verti go, which considerably conti nued to 
aﬀ ect the pati ents’ quality of life.
Main outcome measures: Preoperati ve and postoperati ve quality of life using the 
SF-36 scores and Dizziness Handicap Inventory (DHI) scores.
Results: A total of 17 pati ents (94%) completed the questi onnaire preoperati vely 
and 3 and 12 months postoperati vely. All SF-36 scales of the studied pati ents scored 
signifi cantly lower when compared with the healthy Dutch control sample (p < 0.05). 
There was a signifi cant improvement of DHI total scores and SF-36 scales on physical 
and social functi oning, role-physical functi oning, role-emoti onal functi oning, 
mental health and general health at 12 months aft er surgery when compared with 
preoperati ve scores (p < 0.05). 
Conclusions: Vesti bular schwannoma pati ents with disabling verti go, experience 
signifi cant reduced quality of life when compared with a healthy Dutch populati on. 
Translabyrinthine tumor removal signifi cantly improved the pati ents’ quality of life. 
Surgical treatment should be considered in pati ents with small- or medium-sized 
tumors and persisti ng disabling verti go resulti ng in a poor quality of life.
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Introducti on
Vesti bular schwannoma (VS) pati ents usually present with progressive unilateral 
hearing loss, ti nnitus, balance disorder and in some cases verti go. The incidence 
of rotatory verti go in VS has been reported around 10% of cases, and usually the 
severity and frequency of complaints are diminished because of adequate vesti bular 
compensati on (1-4). However, some VS pati ents conti nue to experience rotatory 
verti go over ti me. 
The unexpected sudden loss of balance or constant illusion of movement, when 
suﬀ ering from rotatory verti go att acks, may impose a great deal of discomfort on 
daily life. The verti go att acks may eventually lead to physical and social limitati ons 
and reduce pati ents’ quality of life (QoL). These conditi ons may refl ect on the medical 
history as perceived by the pati ent and lead to a discrepancy between the pati ents’ 
and the clinicians’ assessment of the verti go. When discussing treatment opti ons in 
cases of VS and verti go, the clinician has, besides clinical parameters, to rely heavily 
on the pati ents’ opinion concerning the incidence or severity of the verti go. As a 
result of this, QoL plays a key role in choice of treatment for these pati ents. 
In VS literature, most studies focus on vesti bular symptoms in general and not 
specifi cally on the concommitant verti go (3,5,6). Several authors have reported on 
QoL aft er microsurgery (7-11) or at the degree of vesti bular compensati on aft er 
surgery (12, 13). Verti go, however, has not been quanti fi ed before in VS pati ents and 
using validated QoL measures. Furthermore, there are few studies in which verti go 
has been discussed as an indicati on for (surgical) treatment in VS. 
Recently, an att empt was made to put ‘vesti bular symptoms’ in VS in a QoL 
perspecti ve at the Consensus Meeti ng on Systems for Reporti ng Results in Acousti c 
Neuroma in Tokyo, 2001 and results were published by Kanzaki et al. (14). The 
objecti ve of the meeti ng was to achieve consensus on a universal reporti ng system. 
According to the vesti bular symptom grading system (grade I–IV), all pati ents in this 
study were classifi ed as grade IV, which is defi ned as: severe, persistent, or almost 
persistent dizziness or dysequilibrium incapacitati ng and severely aﬀ ecti ng quality 
of daily life. All our pati ents were diagnosed with small non-cysti c intracanalicular 
tumors which were suitable for a wait and scan policy. However, these pati ents 
conti nued to experience rotatory verti go att acks and intermitt ent dizziness, despite 
extensive vesti bular rehabilitati on exercises during conservati ve follow-up. Finally, 
these pati ents underwent translabyrinthine surgery to primarily achieve tumor 
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removal and with complete transsecti on of both vesti bular nerves to relieve them 
from their verti ginious complaints. This study aimed to evaluate the QoL results in 
these pati ents and the eﬀ ect of translabyrinthine surgery on the QoL by using the 
validated SF-36 and Dizziness Handicap Inventory (DHI) (15,16).
Materials and Methods
Pati ents
A total of 18 VS pati ents who had been operated between January 2001 and May 
2005 for rotatory verti go were prospecti vely studied. Pati ents were included if they 
had small non-cysti c intracanalicular tumors (with no extrameatal growth) and 
experienced dysequilibrium with rotatory verti go or had multi ple att acks of verti go 
with dizziness during the last year. Our routi ne neurotologic physical examinati on 
included extensive balance testi ng. They were classifi ed according to the relati vely 
new classifi cati on and grading system defi ned by Kanzaki et al. with grade I: 
indicati ng no dizziness or dysequilibrium; grade II: occasional and slight dizziness 
or dysequilibrium; grade III: moderate or persistent dizziness or dysequilibrium 
and grade IV: severe, persistent or almost persistent dizziness or dysequilibrium 
incapacitati ng and severely aﬀ ecti ng quality of daily life (14). All pati ents were 
classifi ed as grade IV and had a non-serviceable hearing on the aﬀ ected ear with an 
average of 56 dB impairment on pure-tone audiogram (range 30-80 dB). Preoperati ve 
balance disorder was also assessed through electronystagmography which showed 
a poor vesti bular compensati on for the majority of the pati ents that could explain 
the severe impact of their symptoms (n = 15). In three pati ents preoperati ve 
electronystagmography could not be performed because of logisti c reasons. Aft er 
review at our multi disciplinary Skull Base Pathology Meeti ng for all pati ents, an initi al 
wait and scanning was decided to await improvement of verti go. However, during 
follow-up and despite extensive vesti bular rehabilitati on exercises no improvement 
of symptoms occurred and pati ents underwent translabyrinthine VS excision. There 
were no postoperati ve complicati ons in any of the pati ents. All pati ents received 
extensive vesti bular rehabilitati on exercises preoperati vely and postoperati vely to 
sti mulate further adaptati on of the vesti bular systems.
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Materials
Pati ents were asked to complete our QoL questi onnaire, which included the validated 
Dutch version of the SF-36 and a Dutch translati on of the validated DHI, preoperati vely 
and 3 and 12 months postoperati vely. Medical data were prospecti vely collected 
from the pati ents’ medical records. 
The Short Form-36 Health Survey
The SF-36 assesses QoL in the following eight domains: physical functi oning, social 
functi oning, role-physical functi oning, role-emoti onal functi oning, mental health, 
general health, bodily pain and vitality. For each domain, there is a series of itemised 
questi ons that are scored. Each score is coded, summed and presented on a scale of 
0-100, where 0 implies the worst possible health status and 100 the best possible. 
Mean scores were compared with the scores from an age- and sex-matched Dutch 
healthy sample (n = 1.063), in order to assess the postoperati ve health status of our 
pati ents with matched healthy controls. The questi onnaire, which included the SF-36 
and DHI, was given to the pati ents at the pre-admission clinic aft er the diagnosis of 
VS was confi rmed. They were asked to complete the same questi onnaire at both 3 
and 12 months aft er surgery.
The Dizziness Handicap Inventory
The Dizziness Handicap Inventory was developed to assess handicap related to 
balance problems. It examines the functi onal, emoti onal and physical defi cits that 
arise secondary to balance problems and previously used in pati ents with verti go 
(17,18). The scale has shown its reliability and validity. The DHI scores range from 0 
(best possible measured health) to 100 (the worst possible). 
Stati sti cal methods
The descripti ve stati sti cs are presented as mean values with standard deviati ons. For 
the analysis of the SF-36, raw scores were calculated for each scale by adding the 
responses for all items on that dimension; each raw score was then transformed 
into a 0-100 point scale using the formula described in the SF-36 scoring manual 
(19). Non-parametric tests were used, because of the non-parametric nature of the 
data. Comparison of conti nuous variables was made using the Wilcoxon signed rank 
test. A 5% level of signifi cance was used. The analysis of DHI scores, used total scores 
rather than the emoti onal, physical and functi onal subscales. This is because, earlier 
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studies have shown by factor analysis that the original subscale structure of the DHI 
is of questi onable validity (20).
Results
A total of 17 pati ents (94%) completed the questi onnaire preoperati vely and 3 and 
12 months postoperati vely. This group comprised 10 women and seven men with a 
mean age of 55.9 years at diagnosis (range, 41-69 yr). Seven pati ents had right sided 
tumors and 10 pati ents had left  sided tumors, which were all intracanalicular. Average 
ti me interval between diagnosis and surgery was 8.4 months. The score distributi on 
of the SF-36 is listed in Table 1. Mean preoperati ve scores were signifi cantly lower 
on all eight scales of the SF-36 when compared with the mean scores of the healthy 
Dutch populati on sample (p < 0.05). There was no signifi cant diﬀ erence between 
preoperati ve scores and 3 months postoperati ve scores (p > 0.05). Scores for physical 
and social functi oning, role-physical functi oning, role-emoti onal functi oning, mental 
health and general health were signifi cantly improved at 12 months postoperati vely 
when compared with preoperati ve scores (p < 0.05). No signifi cant diﬀ erences were 
found between preoperati ve and 12 months postoperati ve scores for vitality and 
bodily pain. To illustrate the eﬀ ects of preoperati ve verti go and of translabyrinthine 
surgery on the SF-36 scales, scores were plott ed in relati on to the scores of individuals 
from the Dutch general populati on (Figure 1). Twelve months aft er surgery, mean 
scores were signifi cantly improved compared with the preoperati ve mean scores, 
but sti ll reduced when compared with the mean scores of a healthy Dutch sample. 
The score distributi on for the DHI is given in Table 2. Total scores showed no 
signifi cant diﬀ erence in preoperati ve scores, and scores at 3 months aft er surgery (p 
> 0.05), but signifi cant diﬀ erences were found between preoperati ve scores and 12 
months postoperati vely (p < 0.05). Analysis was performed to look at possible drivers 
for signifi cant change. For an individual’s DHI score to have changed signifi cantly, 
the change has to be at least 18 points (16). Data were recoded and the pati ents 
experiencing signifi cant change in DHI scores were included in the analysis and 
listed in Table 3. When this 18-point criterion is used, DHI scores were signifi cantly 
improved in 30% of the pati ents and no signifi cant improvement was observed in 
70% of the pati ents at 3 months post-surgery. There were no signifi cantly worse DHI 
scores at 3 or 12 months aft er surgery. At 12 months postoperati vely, 88% of pati ents 
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had signifi cant improvement in DHI scores when compared with preoperati ve scores. 
Hence, for most pati ents, signifi cant improvement in the QoL and verti go can be 
expected only aft er 3 months postsurgery. Age or sex did not signifi cantly correlate 
with changes in SF-36 or DHI scores.
Table 1. Mean SF-36 scores of operated pati ents before and 3 and 12 months aft er 
translabyrinthine surgery (n = 17).
Short 
Form-36 scales
 Before Aft er 3 mo
 
 Aft er 12 mo
 
 Dutch controls
Mean SD Mean SD Mean SD Mean SD
PF 61.5 11.0 67.1 15.7 77.1* 12.8 81.9 23.2
SF 65.7 14.3 70.0 9.9 79.4* 17.1 86.9 20.5
RP 54.4 20.2 58.8 23.2 70.6* 20.2 79.4 35.5
RE 60.7 27.0 66.6 28.9 72.5* 29.4 84.1 32.3
MH 60.2 23.7 60.0 15.6 72.9* 19.6 76.8 18.4
VT 57.9 19.8 62.6 12.3 62.1 17.0 67.4 19.9
BP 65.6 25.4 67.9 24.2 69.7 22.7 79.5 25.6
GH 60.0 12.7 60.0 12.8 70.6* 13.7 72.7 22.7
PF, physical functi oning; SF, social functi oning; RP, role-physical functi oning; RE, role-emoti onal 
functi oning; MH, mental health; VT, vitality; BP, bodily pain; GH, general health; SD, standard deviati on; 
* p < 0.05. 
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Figure 1. Impact of treatment on scores in VS pati ents with disabling verti go. 
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Table 2. Mean total scores of the DHI of operated pati ents before and 3 and 12 months 
aft er translabyrinthine surgery (n = 17).
DHI total Mean Minimum Maximum SD
Preoperati ve 51.3  42 84 13.1
3 months postoperati ve 38.1  20 52   9.1
12 months postoperati ve  19.4  12  40   9.5
DHI, Dizziness Handicap Inventory.
Table 3. The number of pati ents with signifi cant changes in DHI scores.
Change period Bett er No change Worse
Preoperati ve to 3 months postoperati ve  5  12 0
3 months postoperati ve to 12 months postoperati ve  8   9 0
Preoperati ve to 12 months postoperati ve  15   2 0
Discussion
Our study showed that pati ents with small tumors but with persistent and 
disabling verti go complaints have reduced QoL, which signifi cantly improved aft er 
translabyrinthine surgery. It has become clear in personal communicati on with 
colleagues from respected centres that, these kind of VS pati ents are seldomly 
observed and ulti mately most of these pati ents require surgical interventi on. It was 
also concluded that despite numerous QoL reports in VS literature, no previous 
study reported on treatment opti ons (i.e., microsurgery, intra-tympanic gentamycin 
applicati on) when verti go conti nues to aﬀ ect the pati ents’ QoL. There is litt le evidence 
concerning the eﬀ ects of intra-tympanic gentamycin on verti go in VS pati ents. A 
(chemical) labyrinthectomy using intra-tympanic gentamycin is mainly performed in 
pati ents with Meniere’s disease and high success rates are reported. Brantberg et 
al. proposed gentamycin as a treatment in vesti bular diseases other than Meniere’s 
disease, however, only one VS pati ent in their series was treated with intra-tympanic 
gentamycin. They concluded that the intra-tympanic insti llati on with gentamycin may 
further increase symptoms as hearing loss and ti nnitus in these pati ents. Moreover, 
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the underlying mechanism of verti go att acks in vesti bular schwannomas is sti ll not 
completely understood (21). 
Generally, pati ents with small-sized tumors are recommended a wait and scan 
policy, especially when symptoms are mild and QoL is not severely aﬀ ected. All of our 
pati ents had small-sized tumors, but experienced rotatory verti go grade IV (according 
to the classifi cati on proposed by Kanzaki et al. (14)), despite extensive rehabilitati ve 
therapy during follow-up. To relieve them from their verti go and to achieve tumor 
removal, translabyrinthine surgery was fi nally undertaken. Transsecti on of both the 
vesti bular nerves and/or tumorexcision resulted in stability of incoming signals in the 
vesti bular nuclei. Immediately aft er VS surgery, pati ents experienced vesti bular crisis, 
but this acute stage was followed within days or weeks with gradual improvement 
of symptoms due to proper compensati on and adaptati on of the vesti bular nuclei. 
Most of our pati ents, experienced these symptoms only for a few weeks or months 
postoperati vely, but instability of balance has been reported aft er surgery (3,5,22,23). 
Two pati ents conti nued to experience instability of balance even aft er 12 months 
post-surgery and reported no signifi cant change in DHI scores (Table 3). This relati ve 
imbalance is induced by the ablati on of the vesti bular functi on in the operated ear. 
Every pati ent must be informed about this sequelae before surgery, especially in 
whom the surgery is performed to control the verti go. The DHI total scores showed 
signifi cant improvement aft er surgery in 88% of our pati ents at 12 months aft er 
surgery, resulti ng in a postoperati ve score of 19.4 points. When compared with other 
reported DHI scores of pati ents with general vesti bular dysfuncti on or Meniere’s 
disease, our pati ents scored signifi cantly bett er (24,25). Comparison of DHI scores 
with a general VS populati on aft er surgery or with benign paroxysmal positi onal 
verti go pati ents showed no large diﬀ erences (Table 4) (5,6). SF-36 results showed 
that the QoL in VS pati ents suﬀ ering from verti go was signifi cantly reduced on all 
eight scales when compared with Dutch healthy sample. Postoperati vely, scores 
were signifi cantly improved for almost all of the SF-36 scales when compared with 
preoperati ve scores. However, SF-36 results were sti ll lower in pati ents than that of 
the healthy control sample, which is in agreement with the results of previous studies 
(8, 9,10). To our knowledge, there is no previous evidence which reported on the QoL 
or any (surgical) interventi on in a comparable pati ent sample. This may be due to the 
fact that the treatment of VS has focused on tumor excision or preservati on of cranial 
nerve functi on instead of relieving symptoms reported by pati ents.
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Table 4. DHI scores as reported by other investi gators.
First author Mean 
age (yr)
Populati on Mean 
scores
Humphriss et al. (6) 56 aft er vesti bular schwannoma surgery 21.0
El Kashlan et al. (5) 53 aft er vesti bular schwannoma surgery 17.0
Kinney et al. (24) 50 Meniere’s disease 41.0
Enloe et al. (25) 56 general vesti bular dysfuncti on 53.6
Lopez et al. (17) 50 posterior canal benign paroxysmal positi onal verti go 18.1
present study 56 aft er vesti bular schwannoma surgery 19.4
Comparison with other studies
Recently, a prospecti ve study was performed by Myrseth et al. (26) who tried to 
identi fy a relati onship between cochleovesti bular symptoms and QoL in VS by using 
the SF-36 and visual analogue scales. They found that verti go strongly aﬀ ects the 
QoL and suggested that this symptom should play a key role in discussing treatment 
opti ons in small- and medium-sized vesti bular schwannomas. However, they 
concluded that more clinical evidence is needed to confi rm this hypothesis. The 
results of our study seem to contribute to this hypothesis, but the relati vely small 
sample size of the study should be taken into considerati on when interpreti ng the 
study results. Most of our pati ents reported major diﬀ erences between preoperati ve 
and postoperati ve QoL and SF-36 and DHI scores were stati sti cally signifi cant. The 
study was conducted in a prospecti ve manner and by using validated and widely 
used generic and disease-specifi c questi onnaires. In additi on, the SF-36 and the DHI 
have been previously used in studies reporti ng on eﬃ  cacy of treatment of vesti bular 
dysfuncti on. Enloe et al. (25) described a general correlati on between the two scales 
before and aft er vesti bular rehabilitati on interventi on and recommended using the 
two scales together for opti mal QoL assessment in pati ents with vesti bular disorders.
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Conclusions
QoL in VS pati ents with disabling verti go symptoms has not yet been investi gated. It 
concerns a small cohort of pati ents within our VS populati on with verti go symptoms 
that are classifi ed as grade IV according to the classifi cati on of Kanzaki et al. (14). 
This study found that the QoL is reduced in these pati ents despite rehabilitati on 
exercises to control the verti go. Finally, translabyrinthine surgery was performed 
and postoperati ve results show that at 12 months aft er surgery, QoL and verti go 
were signifi cantly improved for most pati ents. Unti l now, evidence for other possible 
treatment opti ons in these pati ents is limited. These fi ndings suggest that surgical 
treatment should be considered in pati ents with small- or medium-sized tumors and 
persistent disabling verti go resulti ng in poor QoL.
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Abstract
Objecti ve: To evaluate functi onal recovery aft er facial-hypoglossal nerve transfer 
with direct coaptati on of the intratemporal part of the facial nerve.
Study Design: Retrospecti ve study.
Setti  ng: University-based terti ary referral center.
Pati ents: Nine pati ents who underwent facial-hypoglossal transfer surgery between 
2001 and 2006 to treat unilateral complete facial nerve palsy.
Interventi on: The facial nerve is mobilized in the temporal bone, transsected at the 
second genu, transferred and directly coaptated to a parti ally incised hypoglossal 
nerve.
Main Outcome Measures: The House-Brackmann grading system was used 
to evaluate facial nerve reinnervati on. Tongue atrophy and movements were 
documented. Quality of life related to facial functi on was assessed using the validated 
Facial Disability Index.
Results: A House-Brackmann Grade III (86%) was achieved in six pati ents, and Grade 
IV (14%) in one pati ent with an average follow-up of 22 months (range, 12-48 mo). 
Two pati ents had a follow-up of less than 12 months aft er surgery, and reinnervati on 
was sti ll in progress. In none of the pati ents who were operated on was tongue 
atrophy or impaired movement observed. Postoperati ve Facial Disability Index scores 
(mean, 71.8 ± (SD) 10.6) for physical functi oning and social functi oning (mean, 85.7 ± 
9.8) were increased for all pati ents when compared with preoperati ve scores (mean, 
28.6 ± 9.0; mean, 37.7 ± 14.4, respecti vely).
Conclusion: The facial-hypoglossal nerve transfer with direct coaptati on of the 
intratemporal part of the facial nerve oﬀ ers good functi onal results with low lingual 
morbidity and improved quality of life. The technique is straightf orward, relati vely 
simple, and should be considered as fi rst opti on for reanimati on of traumati c facial 
nerve lesions. 
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Introducti on
Traumati c facial nerve lesions may potenti ally cause lifelong functi onal, cosmeti c, and 
emoti onal problems (1,2). When facial nerve conti nuity is lost, preferably, immediate 
nerve repair through primary neurorrhaphy with direct coaptati on or graft ing should 
be att empted. When conti nuity is intact, but spontaneous recovery does not occur, 
delayed repair through hypoglossal-facial nerve transfer is a treatment opti on. The 
classic hypoglossal-facial end-to-end nerve transfer (classic HFT) has long been 
advocated as the primary choice (3,4). In this technique, the hypoglossal nerve is 
completely transected and transferred to the facial nerve, which is transected at 
the stylomastoid foramen level, to obtain direct coaptati on. Classic HFT inevitably 
results in hemiglossal paralysis and hemitongue atrophy, which in turn aﬀ ects 
speech, masti cati on, and swallowing in 45% to 59% (5,6). Additi onal disadvantage of 
the classic HFT is hypertonia, spasm, and synkinesis in the facial musculature due to 
massive reinnervati on (5).
In an eﬀ ort to reduce the adverse eﬀ ects of HFT, a number of technical modifi cati ons 
have been applied (Table 1). For instance, only a part of the hypoglossal nerve is 
transsected and transferred by longitudinally splitti  ng (split HFT) (7,8). Functi onal 
results of facial reanimati on are good (100% House-Brackmann Grade III), but all 
pati ents experienced some degree of hemiglossal atrophy. Another modifi cati on of 
the HFT was introduced by May et al. (9) using a “jump” interpositi on graft  between a 
parti ally incised hypoglossal nerve and the facial nerve. Results showed preservati on 
of tongue functi on in 87% of pati ents. However, a longer recovery ti me was observed, 
and facial muscle reanimati on is less than aft er the classic technique. The latt er is 
likely caused by the use of a graft , which causes loss of regenerati ng axons at two 
coaptati on sides. In additi on, morbidity related to harvesti ng of a nerve graft  has 
been reported (10). To avoid the use of a graft , Atlas and Lowinger (11) described the 
transfer of the intratemporal facial nerve to gain facial nerve length and obtain a 
direct coaptati on to the hypoglossal nerve. Since the initi al report of this technique, 
few studies have reported about the outcome of this technique, and only small 
pati ent cohorts are described (12-15). Results of facial functi on are claimed to be as 
good as those in pati ents who underwent classic HFT, however, without additi onal 
defi cits. The purpose of this study was to present this relati vely new modifi cati on and 
evaluate surgical outcome.
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Table 1. Overview of hypoglossal-facial nerve modifi cati ons. 
First author Coaptati on 
technique
N Interval 
from FP to 
RFS (mo)
H-B grade in %  Tongue 
atrophy (n)
II III IV V VI M MO S
Conley and Baker (3) classic 137 2-55  65  18 17  1 70 37
Magliulo et al. (19) classic  10 1-23  40  50 10  2  5  3
Kunihiro et al. (20) classic  42 3 - 33 2  38  52  7 27  7  8
May et al. (9) graft  20 0 - 48  80  15  5 21  1  0
Manni et al. (21) graft  29 4 - > 24 21  45  24  7  3  0  0  0
Arai et al. (8) split   8 1 - 6 100  3  5  0
Atlas and Lowinger (11) direct   3 2-6 100  0  0  0
Donzelli et al. (14) direct   3 12-14  33  67  3  0  0
Sawamura and Abe (12) direct   4 20-37  75  25  0  0  0
Darrouzet et al. (13) direct   6 0-110  83  17  2  0  0
Rebol et al. (15) direct   5 8-13  40  20 20 20  0  0  0
FP, facial paralysis; RFS, rehabilitati ve facial surgery; H-B, House-Brackmann; M, minimal; MO, moderate; 
S, severe; classic, end-to-end HFT; graft , hypoglossal-facial nerve interpositi on jump graft ; split, HFT with 
a split hypoglossal nerve; direct, FHT with direct coaptati on of the intratemporal facial nerve.
Materials and Methods
Pati ents
A total of nine pati ents underwent facial-hypoglossal nerve transfer with direct 
coaptati on (FHT) between August 2001 and May 2006 and were retrospecti vely 
examined. These pati ents presented with a unilateral complete facial nerve paralysis 
aft er surgery for vesti bular schwannoma (n = 5), cerebellar pilocyti c astrocytoma (n 
= 1), cholesteatoma (n = 1), and facial nerve schwannoma (n = 1). One pati ent had 
progressive facial paralysis (H-B Grade V) due to progression of a jugulotympanic 
glomus tumor. The average ti me interval between facial paralysis and reconstructi ve 
surgery was 7.8 months (range, 0-15 mo). Facial nerve functi on was recorded at a 
minimum of 12 months aft er surgery and using the House-Brackmann (H-B Grades 
I-VI) classifi cati on (16). Tongue atrophy was photographically documented and 
separately quanti fi ed by two observers (one of the senior authors and the fi rst 
author) as severe, moderate, low, or absent. Tongue movements were scored as 
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normal of abnormal. Pati ents reported both their preoperati ve and postoperati ve 
facial functi on using the Dutch translated version of the Facial Disability Index 
(FDI) questi onnaire at the end stage of reinnervati on. The FDI is a disease-specifi c, 
selfreport instrument for the assessment of disabiliti es of pati ents with facial nerve 
disorders as perceived from the pati ents’ perspecti ve. It consists of 10 questi ons that 
indicate the level of social handicap (FDI-social) and physical disability (FDI-physical) 
from facial nerve dysfuncti on. Both indices use a 100-point scale with higher scores 
indicati ng less handicap or less disability (17,18).
Surgical technique
A lazy S-shaped paroti d incision was made toward the mastoid ti p and then 
extended along the anterior edge of the sternocleidomastoid muscle to the hyoid 
bone. Identi fi cati on of the extratemporal part of the facial nerve was performed 
using the tragal pointer and posterior belly of the digastric muscle. The facial nerve 
was mobilized in its distal part as far as the trifurcati on in the paroti d gland. The 
sternocleidomastoid muscle was retracted posteriorly for maximal exposure of the 
mastoid process, and the proximal porti on of the facial nerve was dissected free 
up to the stylomastoid foramen (Figure 1A). The mastoid was drilled unti l the facial 
nerve was exposed from the level of the stylomastoid foramen to the external facial 
nerve genu, transected at the external genu and transferred (Figure 1B). In this way, 
additi onal facial nerve length of 1.5 to 2 cm was obtained, allowing for a tensionless 
coaptati on to the hypoglossal nerve. The hypoglossal nerve was found at the level 
of the caroti d bifurcati on and dissected as proximally as possible. A tailor-made 
parti al transsecti on of the hypoglossal nerve was subsequently performed at the 
site where the transferred distal facial nerve would be coapted, which was equal 
to the cross-secti onal diameter of the facial nerve. Usually this was less than half of 
the hypoglossal nerve diameter. A tensionless coaptati on between the two nerve 
endings, the proximal “hemi”-transected hypoglossal nerve and the distal part of 
the facial nerve, was made (Figure 1C). The epineurium and perineurium of the two 
endings were sutured using three Ethilon (Ethicon, Amersfoort, The Netherlands) 
10.0 nylon sutures and Tissuecol (Immuno AG, Vienna, Austria) fi brin glue was 
applied. 
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Figure 1. Intraoperati ve photographs of FHT. A: The 7th (VII) and 12th (XII) nerves are 
dissected, respecti vely (mt: mastoid ti p; dig: digastric muscle). 
Figure 1. B: The stylomastoid foramen (SMF) is dissected and the intratemporal part (VIIt) 
of the 7th nerve is exposed aft er drilling the mastoid ti p (XIIv: verti cal part of the 12th 
nerve). 
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Figure 1. C: The intratemporal 7th nerve is transferred (VIIt) to the verti cal part of the 
12th nerve (XIIv) in an end-to-side coaptati on (CO).
Results
The study comprised 7 female and 2 male pati ents with mean age of 35.4 years 
(range, 9-61 yr). The pati ents’ facial muscle tonus showed fi rst signs of recovery at 
6 months postoperati vely and with movements recorded around the mouth. In 2 
pati ents, follow-up was less than 6 months, and this is too short a period for the 
reinnervati on process. Results of facial nerve functi on in the remaining 7 pati ents 
showed H-B Grade III (86%) in 6 pati ents and H-B Grade IV (14%) in 1 at an average 
follow-up of 22 months aft er surgery (range, 12-48 mo) (Table 2; Figures 2A, B). The 
follow-up ti me in the pati ent with H-B Grade IV was relati vely short (13 mo). Tongue 
atrophy was absent in all pati ents, and tongue functi on was normal (Figure 2C). 
Preoperati ve and postoperati ve FDI subscores are provided in Table 3. There was a 
signifi cant diﬀ erence between preoperati ve and postoperati ve FDI-physical and FDI-
social subscores (Wilcoxon signed rank test, p < 0.05). Average FDI physical scores 
were 28.6 points (SD ± 9.0) preoperati vely and 71.8 points (SD ± 10.6) postoperati vely. 
Average FDI social scores were preoperati vely 37.7 points (SD ± 14.4) and 85.7 points 
(SD ± 9.8) postoperati vely. All 7 pati ents reported improved FDI scores on both sub-
scales. There were no surgical complicati ons in the pati ents who were operated on.
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Table 2. Results and characteristi cs of the pati ents who were operated on.
Pati ent 
no.
Age (yr) Sex Cause of facial 
paralysis
Preoperati ve 
(H-B)
Postoperati ve 
(H-B)
Interval lesion 
-surgery (mo)
Follow-
up (mo)
1. 28 M vesti bular 
schwannoma
VI III  5 12
2. 54 F astrocytoma VI III 12 17
3. 19 F vesti bular 
schwannoma
VI III 15 48
4. 16 F glomus tumor V III  7 12
5. 61 F vesti bular 
schwannoma
VI III  3 32
6. 52 F vesti bular 
schwannoma
VI III  3 20
7. 38 F vesti bular 
schwannoma
VI * 11  3
8.  9 M cholesteatoma VI IV 14 13
9. 38 F facial nerve 
schwannoma
VI *   6
H-B, House-Brackmann; M, male; F, female; * : incomplete follow up, no grading performed.
Figure 2. Case 6. Postoperati ve outcome 12 months aft er this pati ent underwent FHT on 
the right side. A: Pati ents' face at rest.
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Figure 2. B: Pati ent closing both eyes.
Figure 2. C: Pati ent closing her right eye fi rmly by using her tongue and no tongue atrophy 
or lingual hemiparesis is observed.
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Table 3. Mean preoperati ve and postoperati ve FDI scores.
FDI Preoperati ve SD Postoperati ve SD
FDI-physical  28.6   9.0  71.8 *  10.6
FDI-social  37.7  14.4  85.7 *   9.8
FDI indicates Facial Disability Index; * p< 0.05; SD, standard deviati on.
Discussion
The hypoglossal nerve can be used for dynamic rehabilitati on of facial nerve functi on. 
Indicati ons are when the proximal stump of the facial nerve is unavailable or when 
aft er neurootologic surgery, an anatomically intact facial nerve, does not recover in 
ti me. Several modifi cati ons to the classic HFT have been proposed to improve facial 
functi on and minimize tongue functi on defi cits (7-9). In this study, we have used a 
relati vely new technique in which 1.5 to 2 cm of facial nerve is freed from its canal in 
the mastoid bone to perform a direct coaptati on to a restricted part of the hypoglossal 
nerve. Using this technique, in 86% of our pati ents, we achieved the main goals of 
rehabilitati ve facial surgery: functi onal oral sphincter musculature and suﬃ  cient eye 
closure to prevent any eye problems. In additi on, tongue functi on was preserved 
in all pati ents, and no tongue atrophy was observed. Our results confi rm those of 
FHT published by other authors (11-13). The FHT is a relati vely straightf orward and 
easy technique as compared with modifi cati ons with the applicati on of nerve graft s. 
It is also a safer procedure because there is only one nerve coaptati on site. This 
factor reduces the potenti al risk of failure of the reconstructi ve procedure caused by 
dehiscence.
Aft er facial nerve rehabilitati on, pati ents experience some mass movement 
and oft en a nonfuncti onal frontal muscle. In practi ce, functi onal recovery is rarely 
bett er than H-B Grade III. The House-Brackmann grading system is widely used by 
surgeons to grade facial nerve functi on and rate their surgical success, but it does not 
refl ect the pati ents’ percepti on of their surgical results. Therefore, we also evaluated 
outcome using a quality of life (QoL) assessment related to facial nerve functi on 
(17). In this study, signifi cantly higher FDI scores on physical functi oning and social 
functi oning were found aft er surgery as compared with preoperati ve FDI scores. 
Pati ents reported functi onal improvement while eati ng, drinking, or closing the eye, 
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and less social limitati ons related to their facial functi on. However, one should be 
cauti ous while interpreti ng QoL test results. The pati ent sample is small, and the 
preoperati ve facial functi on FDI was scored at the same ti me as the postoperati ve FDI 
score and therefore may be biased. Functi onal nerve recovery is inversely related to 
the interval between nerve lesion and nerve repair (22, 23). The ti ming of hypoglossal 
nerve transfer is diﬃ  cult, especially aft er removal of tumor in the cerebelloponti ne 
angle when facial nerve conti nuity is anatomically spared, but postoperati ve facial 
muscle reinnervati on does not take place. In such instance, we currently perform 
electromyography examinati on of the facial musculature at 6 months. If there are 
no signs of reinnervati on in any of the three facial nerve branches, facial-hypoglossal 
nerve transfer is performed soon aft er.
Conclusion
The facial-hypoglossal nerve transfer with direct coaptati on of the intratemporal part 
of the facial nerve oﬀ ers comparable facial nerve functi on results without lingual 
morbidity. The FHT is relati vely simple and straightf orward and is now our fi rst 
opti on. Our results are comparable to those of alternati ve techniques.
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Abstract
Objecti ve: To evaluate clinical outcome with regard to the amount of residual tumor 
aft er surgery for large vesti bular schwannoma.
Pati ents: Between the period of January 2000 and December 2005 a total of 51 large 
vesti bular schwannoma tumors with extrameatal diameter of 2.6 cm or greater (mean 
32 mm; median 30 mm; range 26-50 mm) were operated using the translabyrinthine 
approach. The extent of the resecti on was intraoperati vely esti mated as complete, 
near and subtotal. The amount of residual tumor was measured and the shape and 
localizati on was scored on gadolinium-enhanced MR imaging. Correlati on between 
intraoperati ve and MRI assessment was performed using the Fisher’s exact test. 
Potenti al growth of residual tumor was documented with frequent MRI follow-up. 
Postoperati ve facial nerve functi on was classifi ed according to the House-Brackmann 
classifi cati on.
Results: Complete resecti on was performed in 26% of the pati ents, near-total 
resecti on in 58% and subtotal resecti on in 16%. MRI showed residual tumor in 46% 
of pati ents (mean, 16.7 mm; SD, ± 8, range, 5-36 mm). Postoperati ve facial nerve 
functi on was House-Brackmann Grades I-II in 78% of the pati ents. The intraoperati ve 
assessment of near-total resecti on did not correlate with postoperati ve MRI (p = 
0.25). Postoperati ve MRI showed either no residual tumor or residue that should 
actually have been classifi ed as a subtotal resecti on. Aft er a follow-up of 4 years (49 
mo; mean, 48 mo), 94% of pati ents did not show changes on MRI.
Conclusions: Tumor control with good facial nerve functi on could be obtained 
in most pati ents. Intraoperati ve assessment did not correlate with the amount of 
residual tumor on postoperati ve MRI. Objecti ve documentati on with postoperati ve 
MRI to measure the extent of removal is therefore mandatory. 
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Introducti on
The outcome of vesti bular schwannoma (VS) surgery is mainly determined by the 
extent of tumor removal and preservati on of neurological functi on. Complete tumor 
removal carries an increased risk of facial nerve paresis, especially in large tumors 
(1,2). To preserve facial nerve functi on and maintain quality of life (QoL), the surgeon 
may leave some tumor in situ. The completeness of tumor removal in surgical 
literature is usually reported in three groups: complete, near or subtotal. Near-total 
(or parti al) resecti on is defi ned as a residue of less than 5% of the original tumor 
size and subtotal resecti on as more than 5% (3). Objecti ve assessment of the actual 
extent of removal documented with postoperati ve gadolinium-enhanced magneti c 
resonance imaging (MRI) scans, however, is scarcely provided (4-10). Intraoperati ve 
assessment of the extent of tumor removal lacks objecti vity. The lack of objecti ve 
postoperati ve MRI data on tumor resecti on has consequences for interpreti ng the 
total outcome of surgical treatment. For instance, postoperati ve facial nerve functi on 
should be signifi cantly bett er when tumor is deliberately left  behind.
In 2001 the consensus meeti ng on VS in Tokyo proposed a system for reporti ng 
surgical results in VS (3). Regarding the amount of residual tumor, it was stated that 
the extent of tumor removal should be confi rmed on postoperati ve gadolinium-
enhanced MRI scans. The size of the residue should be described in two perpendicular 
diameters and with its subsequent localizati on: within the meatus, outside the 
meatus along the cranial nerves and at the brainstem or the cerebellum.
In the present study we report on the surgical results aft er translabyrinthine surgery 
for large vesti bular schwannomas (≥ 2.6 cm) focused on residual tumor. The amount 
of residual tumor as (intraoperati vely) esti mated by the surgeon and the amount of 
residual tumor as documented on postoperati ve MRI scans were compared. When 
residual tumor was present, the locati on and size was further classifi ed according to 
Kanzaki et al. (3). Moreover, correlati on between facial nerve functi on and presence 
or absence of residual tumor and regrowth in ti me was studied.
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Materials and Methods
Pati ents
Between the period of January 2000 and December 2005, a total of 51 VS tumors with 
extrameatal diameter of 2.6 cm or greater were operated using the translabyrinthine 
approach. Pati ents with NF2 or incomplete follow-up were excluded from the 
analysis. One pati ent was lost to follow-up which resulted in 50 pati ents (17 men 
and 33 women) who were retrospecti vely studied. The mean age of the pati ents was 
49 ± 14 years (range, 19-75 yr). The completeness of removal was peroperati vely 
esti mated as complete; near-total or parti al removal, in which less than 5% of the 
initi al tumor was left  in situ, and subtotal removal, in which more than 5% of the 
initi al tumor was left  in situ (3).
Preoperati ve and postoperati ve facial nerve functi on was classifi ed according to 
the House-Brackmann (H-B) classifi cati on (11). Guidelines of the AAO-HNS Committ ee 
on Hearing and Equilibrium were used to classify preoperati ve hearing status (12). All 
50 pati ents preoperati vely had non-serviceable hearing on the tumor ear (Classes C 
and D according to the American Academy of Otolaryngology-Head and Neck Surgery 
(AAO-HNS)).
Preoperati ve tumor size
Preoperati ve tumor size was defi ned using the largest extrameatal diameter on an 
axial 1.5 T MRI T1-image with gadolinium enhancement (Magnevist®, Bayer, Utrecht, 
The Netherlands). The following group classifi cati on was used: intrameatal tumors, 
small tumors (1-10 mm), medium (11-25 mm), large (26-40 mm) and extra large (> 40 
mm) (13). The mean tumor size was 32 mm ± 6.0 mm (range, 26-50 mm). There were 
45 pati ents (90%) with large tumors and 5 pati ents with extra large tumors (10 %).
Residual tumor
The amount of residual tumor was evaluated on postoperati ve 1.5 T MRI (Gyroscan®, 
Philips Medical Systems, Eindhoven, The Netherlands) scans using axial T1-weighted 
sequences with a slice thickness of 1 millimeter, with gadolinium enhancement, and 
fat suppression. According to our standard postoperati ve protocol, a “baseline” MRI 
was performed in all pati ents at a mean of 11 months ± 7 months (range, 2-39 mo) 
aft er surgery. This protocol requires a fi rst MRI scan between 6 and 12 months aft er 
surgery. Of the 50 pati ents, 46 (92%) were scanned within this required interval. 
Surgery for large vesti bular schwannoma: residual tumor and outcome| 107 
During our follow-up program, a second scan (mean 29 ± 9 mo postsurgery; range, 
15-51 mo) and a third scan (mean, 49 ± 17 mo postsurgery; range, 28-94 mo) were 
performed to observe possible changes in enhancement or growth of residue. All MRI 
data were evaluated by the fi rst author and the neuroradiologist (FB) blinded for the 
intraoperati ve assessment data of the surgeons. The largest diameter of the enti re 
enhancement (in millimeters) in any of the axial 1-mm T1-images was measured 
on the baseline postoperati ve MRI scan. The surface (in square millimeters) of the 
preoperati ve tumor and postoperati ve residual tumor was also measured on axial 
MRI scans. 
When interpreti ng MRI scans aft er VS surgery, it is now recognized that slight linear 
high-signal enhancement in the internal auditory canal (IAC) corresponds to dura 
mater infl ammati on or postoperati ve scar ti ssue, whereas nodular enhancement in 
the IAC or cerebello-ponti ne angle (CPA) is suspected for recurrent or residual tumor 
(14,15). Therefore, the enhancement in the IAC and CPA was analyzed for a linear and 
/ or nodular aspect or patt ern. Enhancement patt ern corresponding with dura mater 
infl ammati on or scar ti ssue were not classifi ed as residual tumor. The exact locati on 
of the enhancement was then assessed according to the Kanzaki classifi cati on 
of residual tumor: residual tumor within the meatus, outside the meatus along 
the nerves, or at the brainstem or cerebellum (3). The locati on of the largest part 
(“bulk”) of the enhancement was used and classifi ed according to the classifi cati on 
of Kanzaki. The diﬀ erences within groups and between groups were calculated using 
the Student’s t-test, Chi square test, and the Fisher’s exact test was used to assess 
correlati ons. Stati sti cal signifi cance was set at p < 0.05 (SPSS soft ware version 14.0 
for Windows).
Results
The surgical team intraoperati vely esti mated that in 13 (26%) of 50 cases a 
complete removal was performed and that in 37 pati ents (74%), tumor was left  in 
situ. Of these 37, in 29 (58%) pati ents, a near-total removal was achieved, whereas in 
8 (16%) pati ents a subtotal removal was performed. Regarding the mean preoperati ve 
tumor size, there was no signifi cant diﬀ erence between complete, near and subtotal 
groups (resp. 31, 31 and 34 mm; p = 0.3).
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In 27 (54%) pati ents of the 50 pati ents, enhancement was observed on the fi rst 
postoperati ve gadolinium-enhanced T1-weighted MR images (mean, 11 ± 7 months; 
range, 2-39 months). For these 27 pati ents, the mean diameter of the enhancement 
observed on MRI measured 15.7 mm (SD, ± 8; range, 5-36 mm). Of these 27 pati ents, 
14 pati ents had an enhancement with a linear-nodular confi gurati on, and in 9 
pati ents, an enhancement with a single nodular confi gurati on was observed. In 4 
pati ents, the enhancement had a slight linear confi gurati on (Figure 1A).
Figure 1A. Postoperati ve contrast-enhanced T1 MRI axial scan showing linear 
enhancement in the IAC.
Of the 14 pati ents with a linear-nodular confi gurati on, the largest part of the 
enhancement was located near the brainstem (according to the classifi cati on of 
Kanzaki). Of the 9 pati ents with a single nodular confi gurati on, the largest part of the 
enhancement on MRI was observed just outside the meatus along the facial nerve. 
In 4 pati ents with a slight linear confi gurati on, the enhancement was localized in 
the IAC. In these pati ents the enhancement was not classifi ed as residual tumor. A 
second and third MRI follow-up scan showed an unchanged linear confi gurati on for 
these pati ents.
As a result, 23 pati ents (46%) of the 50 cases had MRI fi ndings corresponding with 
residual tumor (mean, 16.7 mm; SD, ± 8, range 5-36 mm).
All of these 23 pati ents were intraoperati vely classifi ed as either a near-total or 
subtotal removal. There was no residual tumor observed in pati ents intraoperati vely 
classifi ed as complete removal (Table 1). Correlati ons between the intraoperati ve 
esti mati on and the postoperati ve MRI results showed that when the surgeon 
esti mated the removal as either complete or incomplete (near- or subtotal), this 
observati on signifi cantly correlated with the MRI results (p = 0.01). The intraoperati ve 
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assessment of the surgeon regarding the presence of residual tumor may therefore 
be considered as reliable.
Table 1. Postoperati ve MRI assessment of the completeness of tumor removal.
MRI Intraoperati ve assessment
Complete Near-total Subtotal
Residu  0 15 8 23 
No residu 13 14 0 27
Total 13 29 8 50
The group that was surgically qualifi ed as a near-total resecti on (n = 29) had 
residual tumor on MRI in 15 pati ents (mean, 14.6 mm; SD, ± 7.5; range, 5-34 mm), 
whereas in 14 pati ents no residual tumor was observed. In all 8 subtotally operated 
pati ents, residual tumor was present on MRI (20.75 mm; SD, ± 7.7; range, 10-36 mm). 
The mean diameter of the residual tumor on MRI between the group classifi ed as 
near-total and the group classifi ed as subtotal was not signifi cantly diﬀ erent (p = 0.2; 
Figure 1B).
n = 50
n = 23 without 
enhancement
n = 27 with enhancement
(mean 1.57 mm)
-n = 4 with linear 
enhancement
n = 27 no
residual tumor
n = 23 with residual tumor (mean: 6.77 mm)
15 intraoperavely classiﬁed as neartotal
resecon (mean: 14.6mm)*
11 paents classiﬁed as
subtotal resecon
4 paents classiﬁed as
neartotal resecon
8 paents classiﬁed as
subtotal resecon
8 intraoperavely classiﬁed as subtotal
resecon (mean: 20.75mm)
Re-classiﬁcaon of MRI residue**
Figure 1B. Flow chart demonstrati ng the intraoperati ve and postoperati ve MRI 
reclassifi cati on of the amount of residual tumor (*p = 0.2, no signifi cant diﬀ erence in 
tumor size between groups) (**according to the 5% defi niti on: postoperati ve tumor size 
(mm²) / preoperati ve tumor size (mm²) x 100%).
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A near-total removal (or parti al removal) is defi ned by tumor resecti on, of which 
less than 5% of the initi al tumor is left  in situ. A subtotal removal is defi ned by tumor 
resecti on, of which more than 5% of the initi al tumor is left  in situ (3). Of the 23 
pati ents with residual tumor on MRI, the surface area (in square millimeters) of the 
residual tumor was compared to the preoperati ve surface area of the initi al tumor. 
If the amount of residual tumor on MRI was less than 5% of the initi al tumor size, 
then the residual tumor was reclassifi ed as near-total resecti on. If the amount of 
residual tumor on MRI was more than 5% of the initi al tumor, the residual tumor 
was reclassifi ed as subtotal resecti on (Figure 1B). The MRI results show that of the 
15 tumors that were intraoperati vely esti mated as a near-total resecti on, 11 tumors 
were in fact subtotal resecti ons according to the 5% defi niti on. Only 4 tumors that 
were intraoperati vely assessed as a near-total resecti on were actually classifi ed 
as near-total resecti on on the postoperati ve MRI (according to the 5% defi niti on; 
Table 2; Figure 1C and D). All of the 8 tumors that were intraoperati vely esti mated 
as a subtotal resecti on were classifi ed as subtotal resecti on on postoperati ve 
MRI (according to the 5% defi niti on; Table 2; Figure 1E and F). The intraoperati ve 
assessment regarding near-total resecti on did not correlate signifi cantly with 
postoperati ve MRI results (p = 0.25). The esti mati on of the surgeon regarding a near-
total removal can therefore not be considered as reliable.
Table 2. MRI classifi cati on of residual tumor for the near- and subtotal (sub)groups. 
MRI measured residu Intraoperati ve assessment
Near-total Subtotal Total
Near-total   4* 0   4
Subtotal  11* 8 19
Total 15 8 23
* p = 0.25.
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Figure 1C. Preoperati ve contrast-enhanced T1-weighted MRI axial scan showing a tumor 
with a diameter of 43 x 30 mm.
Figure 1D. Postoperati ve contrast-enhanced T1-weighted MRI axial scan showing residual 
tumor with a diameter of 10 x 6 mm. The resecti on was classifi ed as near-total both 
intraoperati vely and aft er reclassifi cati on on MRI.
Facial nerve outcome
Facial nerve outcome in relati on to completeness of removal is presented in Table 
3. In 39 pati ents (78%), H-B Grades I to II were achieved at an average of 12 months 
(SD, ± 4 mo) (range, 2-24 mo) postoperati vely. In 11 pati ents (22%), there were H-B 
Grades III to IV. In 2 of these pati ents, the facial nerve was anatomically not intact, 
and facial nerve reconstructi on was performed. In 1 pati ent, a sural nerve graft  was 
directly interposed, and in the other a (delayed) facial-hypoglossal nerve transfer 
with direct coaptati on of the intratemporal part of the facial nerve was performed 
(16). Finally, in both pati ents, H-B Grade III was achieved. There were no pati ents with 
H-B Grades V to VI.
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Figure 1E. Preoperati ve contrast-enhanced T1-weighted MRI axial scan showing a tumor 
with a diameter of 28 x 20 mm. 
Figure 1F. Postoperati ve contrast-enhanced T1-weighted MRI axial scan showing a 
residual tumor with a diameter of 15 x 8 mm. The resecti on was classifi ed as subtotal 
both intraoperati vely and aft er reclassifi cati on on MRI.
In the near-total and subtotal operated group, a relati vely high number of pati ents 
have a favorable facial nerve outcome (H-B Grades I-II) when compared with pati ents 
with complete resecti ons, although this diﬀ erence was not stati sti cally signifi cant 
(p = 0.4; Table 3). In our series, facial nerve outcome did not correlate signifi cantly to 
tumor size (p = 0.6). 
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Table 3. Facial nerve outcome according to completeness of removal (n = 50).
Complete Near-total Subtotal
Grades I-II  9* 22* 8* 39
Grades III-IV  4  7 0 11
Grades V-VI  0  0 0  0
Total 13 29 8 50
* p = 0.4. 
In Table 4, facial nerve outcome is presented in relati on to residual tumor on MRI. 
Facial nerve functi on H-B Grades I to II was equally distributed in the residual tumor 
group as in the group without residual tumor on MRI. An unfavorable facial nerve 
outcome (H-B Grades III-IV) was mainly found in pati ents without residual disease 
(n = 8) when compared to pati ents with residual tumor (n = 3). This diﬀ erence was, 
however, stati sti cally not signifi cant (p = 0.17). Facial nerve results did not signifi cantly 
diﬀ er between near or subtotal resecti ons when controlling for age or tumor size 
(p = 0.06). 
Table 4. Facial nerve functi on in relati on to residual tumor on MRI (n = 50).
Grades I-II Grades III-IV Grades V-VI
Residu 20  3* 0 23
No residu 19  8* 0 27
Total 39 11 0 50
*p = 0.17.
MRI documented growth of residual tumor
In 40 of 50 pati ents, a second follow-up MRI was performed (mean, 29 mo; SD, ± 9; 
range, 15-51 mo). In 10 of the 50 pati ents, there was no indicati on for a second MRI 
because the initi al resecti on was esti mated as complete and the fi rst MRI showed no 
residual tumor. Of the 40 pati ents, 23 had residual tumor on the fi rst MRI, and the 
other 17 had no residual tumor on the fi rst MRI. Twenty pati ents with residual tumor 
on the fi rst MRI could be followed on a second MRI, and 3 were lost to follow-up 
due to death (n = 2; both not VS related), and 1 pati ent refused follow-up imaging. 
For these 20 pati ents with residual tumor on fi rst MRI, 18 showed no change on 
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the second MRI. In 2 pati ents, outgrowth of residual disease was observed at a 
mean of 36 months aft er surgery (SD, ± 9; range, 30-42 mo). In these pati ents, the 
residual disease had a linear-nodular confi gurati on and was located at the brainstem 
(according to the Kanzaki classifi cati on). One pati ent was lost to follow-up before a 
third MRI scan could be made. In the remaining 17 residual tumor pati ents, a third 
MRI scan could be performed (mean, 49 mo; SD, ± 17; range, 28-94 mo), of which 
16 showed no change. One pati ent clearly demonstrated outgrowth at 28 months 
postoperati vely aft er an initi al subtotal resecti on. The residual disease had a single 
nodular confi gurati on that was located just outside the meatus and along the facial 
nerve. In the 17 pati ents who had no residual tumor on the fi rst MRI, no growth 
could be detected on the second MRI.
As a result MRI documented outgrowth of residual tumor was observed in 3 (6%) 
of the 50 pati ents and aft er a follow-up of 4 years.
Postoperati ve complicati ons 
As shown in Table 5, postoperati ve complicati ons occurred in 15 pati ents. There 
were no deaths related to the TL surgery, and most complicati ons were transient. 
Cerebrospinal fl uid (CSF) leakage was most frequently observed (n = 10), and most 
of these pati ents were treated with a lumbar drain. Three of these had to be treated 
for bacterial meningiti s. In 5 pati ents, transient neurological complicati ons occurred 
such as peroneal nerve apraxia, ataxia, or transient cranial nerve paresis. 
Table 5. Postoperati ve complicati ons (n = 15)*.
Complicati on No. of pati ents
CSF leakage treated with lumbar drainage 8
CSF leakage treated with revision surgery 1
CSF leakage treated conservati vely 1
Transient neurologic dysfuncti on 5
Bacterial meningiti s 3
Postoperati ve hematoma requiring surgical drainage 2
Decubital ulcers 2
Sigmoid sinus thrombosis 1
Acute Respiratory Distress Syndrome 1
* Some pati ents experienced more than 1 complicati on.
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Discussion 
This study evaluated the results of surgical treatment of large VS with a focus on the 
amount of postoperati ve residual tumor and facial nerve outcome. The preoperati ve 
surgical strategy was to obtain complete tumor removal in all cases. This strategy was 
intraoperati vely abandoned when strong tumor adhesions with brainstem and/or 
cranial nerves were encountered. In these instances, the surgeon decided to leave 
some tumor remnant behind so as not to jeopardize cranial nerve functi on. Overall, 
this surgical strategy resulted in removal that could be divided in 3 groups. Complete 
resecti on was obtained in 26% of the pati ents. In the 74% of pati ents in which 
tumor was left  in situ, 58% was classifi ed as near-total resecti on and 16% as subtotal 
resecti on. Interesti ngly, contrast-enhanced MRI 1 year postoperati vely showed 
residual tumor in only 46% of pati ents. MRI did not show residual disease in the 
group that was surgically judged as complete resecti on. Apparently, in this group, the 
surgeon could reliably esti mate whether the removal was complete or incomplete. 
All of the tumor remnants in the subtotal group were detected on MRI. Only the 
surgical assessment in the near-total group did not match the postoperati ve MRI 
images. Surprisingly, in approximately half of the pati ents in the near-total resecti on 
group, tumor remnants could not be dectected on MRI. This remained so on follow-
up imaging. Surgical assessment in the near-total resecti on group in this respect was 
therefore too pessimisti c. 
Compared to MRI documentati on, in about the other half of the tumors that were 
intraoperati vely esti mated as near-total resecti on, the amount of residual tumor 
should have been classifi ed as subtotal resecti on. The drawback of this comparison is 
the 2-dimensional assessment of the preoperati ve tumor and postoperati ve residual 
tumor. A comparison of tumor volumes would have been more accurate, but such 
data could not be generated from our MRIs (17). However, we feel that our main 
conclusion will not be majorly aﬀ ected by this drawback. 
We hypothesize that in approximately half of the pati ents with near-total 
resecti ons, postoperati ve tumor regression may have taken place. A possible 
explanati on might be postoperati ve tumor necrosis aft er devascularisati on. Residual 
remnants have been shown to be relati vely avascular in VS managed with staged 
tumor resecti on (18). 
At the consensus meeti ng on VS (2001), it was proposed that the intraoperati ve 
assessment of the extent of removal lacks objecti vity, and that residual tumor should 
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be documented with MRI. Sofar, the surgeon’s esti mati on of completeness of tumor 
removal sti ll holds as the gold standard in the recent literature and not the objecti ve 
gadolinium-enhanced MRI documentati on. For instance, both Lanman et al. (8) and 
Briggs et al. (6) reported an extent of resecti on up to 96%. In these studies, it was 
not clearly menti oned whether postoperati ve MRI assessment was performed. More 
recently, others did use postoperati ve imaging. Unfortunately, a clear picture of the 
amount of residual tumor was not provided. In additi on, imaging methods were not 
clearly described, and ti me intervals between surgery and imaging were not given 
(9,19-21).
Compared to other reports on the surgical treatment of large tumors, we achieved 
comparable facial nerve outcome (78%; H-B Grades I-II) (18-24). The size of the tumor 
and the surgeon’s experience are pre-operati ve predictors for postoperati ve facial 
nerve functi on. The outcome of facial nerve functi on in our series appeared not to 
be related to initi al tumor size. Moreover, no signifi cant diﬀ erence in facial nerve 
outcome was found between the subtotal or near-total resecti on groups. When 
residual tumor was left  behind, facial nerve outcome was more favorable. This 
relati onship was, however, not stati sti cally signifi cant. Park et al. (22) reported a 
preserved facial nerve outcome in 78% of cases aft er surgery for large VS and found 
an inverse correlati on between facial nerve preservati on and the extent of removal. 
Bloch et al. (23) reported favorable facial nerve outcome (H-B Grades I-II) in 81% 
of pati ents aft er incomplete VS resecti on. Postoperati ve MRI in their series showed 
that 20% of near-total and 80% of subtotally operated pati ents had visible residual 
disease. According to the authors, the absence of residual tumor in the subtotal 
resecti on group was caused by tumor regression due to devascularisati on of the 
tumor remnants. However, the surgeon’s intraoperati ve assessment regarding the 
extent of the removal might have been too pessimisti c, as was the case in our series. 
Raft apoulos et al. (24) also performed MR imaging aft er surgery for large VS in order 
to assess their rate of tumor removal and found residual tumor in 31% of cases with 
preserved facial nerve functi on in almost all pati ents. In our opinion, preservati on 
of facial nerve functi on is not primarily related to tumor size. We think that the 
vulnerability of the facial nerve is especially related to the course it takes over the 
tumor capsule, whether the nerve is stretched out and whether it is anatomically 
recognizable or only by sti mulati on.
To clearly disti nguish actual residual tumor from dura mater infl ammati on or 
postoperati ve scar ti ssue, we described the confi gurati on of the residue. In 4 of 
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the 27 pati ents, a linear confi gurati on was observed within the IAC. Because of this 
confi gurati on, we did not consider it as residual tumor. The dural enhancements 
observed in these 4 pati ents remained unchanged even aft er a follow-up of more 
than 3 years. The other (nodular) confi gurati ons corresponded with residual tumor 
and were localized near the brainstem or just outside the meatus along the facial 
nerve. 
Recurrence was defi ned as MRI-documented outgrowth of residual tumor and 
was observed in 3 pati ents (6%) aft er a follow-up of more than 4 years. Of these 
pati ents, 2 had initi ally been operated subtotally, and 1 pati ent near-total. Two 
pati ents underwent reoperati on mainly because their growing residue was linear-
nodular and localized near the brainstem. 
The presence or absence of tumor remnants aft er surgery is a major outcome 
measure. In this series, it appears that adequate intraoperati ve assessment of the 
extent of resecti on was very diﬃ  cult, especially in the near-total resected tumors. 
Postoperati ve MRI to objecti vely measure the extent removal is therefore needed. 
Conclusion 
In this study, the preoperati ve surgical intenti on was to achieve complete tumor 
removal in large VS with preservati on of facial nerve functi on. Magneti c resonance 
imaging-documented residual disease was observed in 46% of pati ents. In most 
pati ents, the residual tumor had a linear-nodular confi gurati on and was located 
near the brainstem. Tumor control could be obtained in 94% of the pati ents. 
Recurrence mostly occurred in pati ents aft er subtotal resecti ons with a linear-
nodular confi gurati on of the residual tumor localized at the brainstem. Postoperati ve 
facial nerve functi on was H-B Grades I to II in 78% of the pati ents. A trend between 
absence or presence of residual tumor and facial nerve functi on was observed; 
however, stati sti cally not signifi cant. Intraoperati ve assessment of the amount of 
residual tumor did not correlate well with the amount of residual tumor on the MRI 
scan. Postoperati ve residual tumor documentati on should always be performed 
to provide a basis for assessment of recurrent disease and for interpretati on of 
functi onal outcome.
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Chapter 8
General discussion and conclusion 
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The overall aim of this thesis was to examine the outcomes of current treatment 
opti ons for vesti bular schwannoma (VS) with an emphasis on pati ent reported 
outcomes (PROs). First, we described quality of life (QoL) outcome, illness percepti ons 
(IPs) and coping behavior in pati ents with VS at diagnosis. Secondly, we investi gated 
QoL and important clinical aspects in pati ents with VS who were treated either with 
wait and scan, microsurgery or radiosurgery. 
Nowadays, major technical advances have ensured that the treatment of VS no 
longer involves life saving surgery but rather prophylacti c management of future 
morbidity in most pati ents. As part of these advances, relati vely new treatment 
opti ons have evolved such as a wait and scan policy or stereotacti c irradiati on (1-12). 
However, the diversity in available opti ons does not necessarily facilitate the choice 
of treatment. Microsurgery implies that a pati ent has to undergo major skull base 
surgery for tumor removal with signifi cant risk of morbidity including facial nerve 
palsy and hearing loss, while radiosurgery is non-invasive and aims at tumor control. 
Radiosurgery further carries less risk of cranial nerve defi cit, while conservati ve 
treatment generally implies tumor surveillance unti l tumor progression is observed. 
As a result, all current opti ons have completely diﬀ erent treatment goals and criteria 
of success. Moreover, VS pati ents increasingly have their own prioriti es regarding 
treatment. Each treatment therefore, may have enti rely diﬀ erent consequences 
for the life of VS pati ents. From this point of view, PROs such as QoL may provide 
valuable informati on in additi on to the traditi onal outcome measures. Recently, it 
was also recognized that besides these conventi onal measures, psychological factors 
could play an important role in determining the pati ent’s QoL (13-15). 
In this thesis, we could not identi fy signifi cant relati onships between conventi onal 
measures and QoL outcomes. 
For instance, deteriorati on of hearing loss was most reported, but this did not 
seem to meaningfully interfere with QoL (Chapters three and four). This could be 
explained by the fact that the majority of symptoms were already present before 
treatment or that pati ents gradually adjusted to them over ti me due to response 
shift  (16). 
Although dizziness and especially verti go are not a common symptom in VS, they 
are recently thought to be predicti ve in QoL percepti on (17). We did not observe such 
strong relati onships, but results from Chapter fi ve showed that QoL was impaired 
in VS pati ents with verti go to such a degree that fi nally microsurgery was chosen. 
This study has very well displayed that impaired QoL can be a decisive factor in 
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VS treatment. Hence, in VS pati ents with disabling symptoms such as verti go, QoL 
assessment is crucial to further opti mize VS treatment. 
Tinnitus is the second most frequent symptom in VS and its development aft er 
treatment is generally thought to be unpredictable, but a slight overall increase 
has been observed. Tinnitus developed in a small number of conservati vely treated 
pati ents, but without signifi cant impact on QoL (Chapter three). Aft er radiosurgical 
treatment, inverse correlati ons were found between ti nnitus and the physical 
domains of QoL (Chapter four). Apparently, ti nnitus may aﬀ ect QoL in VS pati ents to 
some degree, but it is limited to daily physical tasks. Pati ents did not experience any 
emoti onal handicap from ti nnitus, as frequently has been described (18). 
In pati ents with facial nerve defi cit or trigeminal symptoms, reduced QoL scores 
were observed compared to other VS pati ents, but diﬀ erences were not signifi cant 
(Chapter three and four). There has been some inconsistency with regard to the 
eﬀ ects of facial nerve impairment on QoL aft er treatment for VS. Some studies 
report a signifi cant negati ve eﬀ ect on QoL, whereas others do not (19-21). A possible 
explanati on might be the use of the SF-36 which has slight limitati ons with respect to 
otolaryngologic interventi ons (22,23). The use of an additi onal disease- or symptom-
specifi c questi onnaire could prevent these kinds of problems. 
In Chapter six, we demonstrated that pati ents with facial nerve palsy actually 
experienced signifi cant functi onal and psychological morbidity. A disease-specifi c 
measure, the Facial Disability Index (FDI) was used to rate impact of pati ents’ facial 
functi on on QoL, which was signifi cantly impaired. Aft er facial-hypoglossal nerve 
transfer surgery, most pati ents experienced functi onal oral sphincter musculature 
and suﬃ  cient eye closure to prevent any eye problems. In additi on, tongue functi on 
was preserved in all pati ents and no tongue atrophy was observed. Despite the 
small number of pati ents, we found signifi cantly bett er QoL aft erwards. It was the 
fi rst report in which QoL was assessed aft er rehabilitati ve facial-hypoglossal nerve 
surgery. 
Although it is generally known that pati ents with larger tumors experience 
increased tumor-related morbidity, we found that QoL did not diﬀ er between 
pati ents with small or large tumors. For instance, in the microsurgical treatment of 
large VS, tumor excision carries increased risk of facial nerve paralysis. To preserve 
facial nerve functi on and maintain pati ents’ QoL, the surgeon may therefore leave 
some tumor in situ. In Chapter seven we hypothesized that postoperati ve facial 
nerve functi on should be signifi cantly bett er when tumor is deliberately left  behind. 
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We found that when residual tumor was left  behind, facial nerve outcome was more 
favorable. This relati onship, however, was not stati sti cally confi rmed, probably due 
to the small sample. In our center, facial nerve outcomes aft er surgery were favorable 
and comparable to the results from renowned clinics (24-27).
From the abovementi oned results, it appears that QoL is not merely determined 
by the size of the VS or concomitant symptoms but may also be infl uenced by the 
burden of suﬀ ering from the disease itself. Therefore, we also explored whether 
psychological factors may contribute to QoL in VS pati ents (Chapter two). In an 
untreated VS pati ent sample, a poor acti ve and passive coping style was observed 
compared to other pati ent groups. In general, pati ents were shown to perceive their 
tumor as an acute and life-threatening illness. Consequently, in this pati ent sample 
QoL was found to be impaired compared to norms and other comparable pati ent 
populati ons, which corresponds to previous data (17). However, QoL was measured 
before treatment and pati ents might not yet have been able to understand the 
consequences of their illness. Nevertheless, the results are important and have 
implicati ons for clinicians as well as for the pati ent’s caretakers. 
Now, we can conclude that QoL in VS pati ents mostly depends on how they 
perceive their illness and to what extent they cope with it. The eﬀ ects of conventi onal 
measures such as tumor size and symptoms on QoL are limited, which is in line with 
previous published data (28-38). 
For future research, we may be able to improve QoL by an interventi on in the fi eld 
of IPs, as recently described in cardiac pati ents (39). Our pati ents could be referred to 
a medical psychologist, who could then assist them in adapti ng to their VS. 
The results of Chapter two are highly relevant when exploring QoL for current 
treatment in VS, because baseline data were provided for comparison of QoL 
outcomes between pati ents either treated conservati vely or with microsurgery or 
radiosurgery. When compared to the untreated pati ent sample from Chapter two, 
improvement of QoL was observed for all three treatment modaliti es. We hypothesize 
that aft er treatment, VS pati ents experienced their illness as being ‘controlled’ or 
cured and without signifi cant morbidity. In contrast, the tumors of the pati ents in 
Chapter two were not treated yet. 
The results of our observati onal study (Chapter three) were encouraging, because 
in the past, the presumed impact of a wait and scan policy on QoL has generally been 
used as an argument to proceed to microsurgery. So far, there has been a paucity 
on the QoL subject in conservati ve treatment of VS. Our data were prospecti vely 
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collected over a period of almost four years, which is unique when reviewing the 
current literature. However, follow-up is sti ll short given the slow growing character 
of VS. Our study failed to assess QoL in the enti re observed cohort, which may limit 
the interpretati on of these data. However, in a recent study, QoL was not found to 
be further impaired in VS pati ents who had failed conservati ve treatment (40). As in 
our study, others also reported on stable QoL in observed VS pati ents, but without 
the use of baseline and postt reatment data (41). In our opinion, therefore, we have 
provided strong evidence that a wait and scan policy does not adversely aﬀ ect QoL 
in VS pati ents. 
Despite the favorable outcome of our radio- and microsurgical samples, QoL 
of these pati ents was sti ll impaired when compared to their control samples. 
While radiosurgical treatment of VS is less invasive than microsurgery, it may sti ll 
induce several complaints such as hearing loss, ti nnitus, decrease of facial nerve 
functi on, facial pain and dysbalance. Complicati ons of radiosurgery have also been 
reported, although the consequences for pati ents are oft en less serious compared 
to complicati ons aft er microsurgical treatment. In those pati ents who experienced 
complicati ons in our studies, a signifi cant QoL impairment was not observed. One 
possible explanati on might be that complicati ons were oft en transient and in a 
small number of pati ents. Moreover, QoL was generally assessed some ti me aft er 
treatment.
The QoL outcomes of the operated pati ents were comparable to the radiosurgically 
as well as the conservati vely treated VS pati ents. From a QoL point of view, the 
three pati ent groups did not seem to diﬀ er signifi cantly, although there are major 
diﬀ erences in terms of pati ent and tumor characteristi cs. Our results were confi rmed 
by a recent prospecti ve study using the SF-36 measure at regular intervals, which also 
concluded that there were no QoL diﬀ erences between the three current modaliti es 
(42).
Throughout our studies, we have used validated generic questi onnaires to 
measure QoL. However, for opti mal QoL assessment, we recommend the use of 
generic measures in combinati on with disease- or symptom-specifi c measures as 
described in Chapter fi ve. Our methods consisted of solid QoL instruments, but for 
future research, it would be preferable to use a VS-specifi c questi onnaire in additi on 
to those currently used. Such a questi onnaire could focus more on the parti cular 
problems encountered when suﬀ ering from VS. However, no validated VS-specifi c 
measure exists so far.
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The results of this thesis have led to a more conservati ve approach for VS pati ents 
in our department. Nowadays, an initi al wait and scan policy for our pati ents with 
small- or medium-sized tumors is increasingly adopted. In case of tumor progression 
or increase of symptoms, acti ve treatment is oﬀ ered to these pati ents. At the LUMC, 
microsurgery is generally oﬀ ered to pati ents with growing tumors depending on 
pati ent and tumor factors. As recognized by others, microsurgery is also our fi rst 
choice in the treatment of large tumors. However, from our research and from 
published reports world-wide, we are convinced that radiosurgery has become a 
well-established treatment opti on for VS next to microsurgery.
Our study did not aim to compare outcomes of the diﬀ erent modaliti es in order 
to claim ‘the best treatment opti on for VS’. In our opinion, there is no clear opti on of 
what would be best for all individuals and it would not even be possible to conclude 
this from our studies. Given our results, and the state-of-the-art with regard to the 
medical management of pati ents with VS, it can be concluded that future research 
should focus on a number of issues. First, the development of a specifi c QoL measure 
for pati ents with VS would be helpful. Secondly, a head to head comparison of the 
treatment modaliti es for pati ents with VS would shed light on crucial questi ons about 
which treatment is best for which pati ents, taking QoL into account. Thirdly, further 
research should focus on developing self-management interventi ons in pati ents with 
VS, most likely with the inclusion of partners of the pati ents, and with QoL as the 
central outcome measure. VS is an area with exciti ng research and clinical challenges. 
This thesis has att empted to contribute to the area.
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Vesti bular schwannomas are benign intracranial tumors which generally arise 
from the Schwann cells of the superior part of the vesti bular porti on of the eight 
cranial nerve. The most common symptoms accompanying vesti bular schwannoma 
(VS) are unilateral hearing loss, ti nnitus, verti go and unsteadiness. For many years, 
microsurgical treatment of VS has been considered the ‘gold standard’. However, 
the treatment of VS conti nues to evolve with the advent of alternati ve treatment 
opti ons such as wait and scan and stereotacti c irradiati on. Moreover, advances in 
MRI techniques have allowed for an early diagnosis and exact measurement of 
growth, which has led to an increased number of pati ents with small and minimally 
symptomati c tumors. As a result, the treatment of VS no longer involves life saving 
surgery, but prophylacti c management of future morbidity. These developments have 
also created new insights into how vesti bular schwannoma can be best treated, as it 
has become clear that the tumor may remain unchanged for many years. However, 
the treatment of VS pati ents sti ll remains a matt er of debate with advocates and 
opponents of each modality. Traditi onally, the evaluati on of VS treatment was 
performed using primary outcome measures such as mortality and morbidity. But 
the subject of quality of life (QoL) has increasingly become an important outcome 
measure in VS. QoL may provide clinicians valuable informati on that is not always 
supplied by traditi onal outcome measures. This thesis describes how VS pati ents 
perceive their QoL at diagnosis and further explores QoL and outcomes in pati ents 
treated with observati on, microsurgery or radiosurgery.
Chapter one gives a general introducti on with a short review of the current 
opti ons and pati ent's percepti ons and describes treatment outcomes in VS. At the 
end of this chapter, the aim and outline of the study are delineated.
In Chapter two QoL outcome, illness percepti ons (IPs) and coping behaviour in VS 
pati ents at diagnosis are presented. To assess IPs and coping behaviour, the Illness 
Percepti on Questi onnaire - Revised (IPQ-R) and Utrecht Coping List (UCL) were used. 
QoL was measured using the SF-36, a validated generic QoL measure. A prospecti ve 
analysis in 79 pati ents with small- and medium-sized VS demonstrated that IPs and 
coping, but especially QoL in VS pati ents, were not as good as reference values. 
Untreated VS pati ents also showed to have poor acti ve and passive coping styles 
and seek less social support compared to other pati ents. The results from this study 
indicate that VS pati ents are a group of pati ents that suﬀ er from the moment of their 
diagnosis. This may have implicati ons for clinical decision making and for opti mizing 
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interacti on with pati ents. Changing IPs and coping by means of an interventi on may 
improve QoL in VS pati ents.
Chapter three investi gates how the tumor, the cardinal symptoms, and QoL 
developed during follow-up in wait and scanned VS pati ents. A total of 70 vesti bular 
schwannoma pati ents who were initi ally included in the wait and scan protocol were 
followed with a mean observati on ti me of 43 months. All pati ents had small- or 
medium-sized tumors when they were included in the protocol. QoL was measured at 
diagnosis and at the end of follow-up in those pati ents who were sti ll conservati vely 
treated and by using the SF-36. The study group was characterized by non-growing 
small tumors and relati vely stable symptoms over ti me. We found that conservati ve 
observati on did not signifi cantly aﬀ ect QoL in these pati ents. Most of the tumors did 
not grow and useful hearing was preserved in more than half of the pati ents with 
useful hearing. Initi al conservati ve observati on is therefore a safe opti on for pati ents 
with smaller tumors. There was no signifi cant relati onship between cochleovesti bular 
symptoms and QoL. However, progression of hearing loss was observed during 
follow-up. Pati ents should be counseled regarding this risk before treatment.
Chapter four retrospecti vely reports on QoL and important clinical aspects in 
VS pati ents aft er radiosurgery. Seventy-two consecuti ve, newly-diagnosed pati ents 
with unilateral VS underwent linear accelerator-based radiosurgery with marginal 
tumor doses of 1 x 12 Gy. A total of 64 pati ents fi lled out the SF-36 questi onnaire and 
scores of these pati ents were compared with SF-36 scores of the general sample. 
Local tumor control and symptoms were also studied. The results showed favorable 
tumor control rates and low postt reatment morbidity aft er a mean follow-up of 34 
months. In general, few pati ents reported progression of symptoms and QoL did 
not signifi cantly correlate with any of these symptoms. Aft er treatment, QoL scores 
were moderately aﬀ ected when compared to norms. It was concluded that QoL 
aft er radiosurgical treatment for VS was impaired. Radiosurgery oﬀ ered good tumor 
control and favorable clinical outcome similar to other published reports. This report 
is one of the few studies that describe QoL in VS pati ents aft er low dose radiosurgery. 
The results may be valuable when counseling pati ents with small- or medium-sized 
VSs, for which a radiosurgical treatment has increasingly become a treatment opti on.
Chapter fi ve determines the impact of translabyrinthine (TL) surgery on QoL in 
VS pati ents with disabling rotatory verti go. A total of 18 pati ents with a unilateral 
intracanalicular VS, without serviceable hearing in the aﬀ ected ear and severely 
handicapped by att acks of rotatory verti go were prospecti vely studied. Despite an 
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initi al conservati ve treatment, extensive vesti bular rehabilitati on exercises, TL surgery 
was performed because of the disabling character of the verti go. Preoperati ve and 
postoperati ve QoL was measured using the SF-36 and DHI. Preoperati ve QoL was 
reduced because of the disabling verti go, but signifi cantly improved aft er TL surgery. 
However, QoL was sti ll reduced when compared to the general sample. Unti l now, 
evidence for other possible treatment opti ons such as (chemical) labyrinthectomy 
or radiosurgical treatment in these pati ents is limited. From our study, it may be 
concluded that TL surgery signifi cantly improved the pati ents’ QoL and surgical 
treatment should be considered in pati ents with small- or medium-sized tumors and 
persisti ng disabling verti go.
In Chapter six, we used a new variati on of the facial-hypoglossal nerve coaptati on 
to reanimate the paralyzed facial musculature aft er (surgical) trauma. With this 
technique 1.5 to 2 cm of the facial nerve is freed from its canal in the mastoid bone 
to perform a direct coaptati on to a restricted part of the hypoglossal nerve. The 
technique avoids the use of a graft  and is thereby a safer procedure because there 
is only one nerve coaptati on site. This factor reduces the potenti al risk of failure of 
the reconstructi ve procedure caused by dehiscence. Another advantage compared 
to other facial-hypoglossal techniques is that the hypoglassal nerve is only partly 
incised which reduces the risk of hemiglossal paralysis or hemitongue atrophy. Facial 
nerve outcome was evaluated using the House-Brackmann grading system, which 
is widely used by surgeons to grade facial nerve functi on, but also using the Facial 
Disability Index (FDI), a frequently used QoL questi onnaire related to facial nerve 
functi on.
In the majority of our pati ents, we achieved the main goals of rehabilitati ve facial 
surgery: functi onal oral sphincter musculature and suﬃ  cient eye closure to prevent 
any eye problems. In additi on, tongue functi on was preserved in all pati ents, and 
no tongue atrophy was observed. Clinical and QoL outcomes of our technique were 
similar to published results by other authors. Functi onal improvements were reported 
while eati ng, drinking, or closing the eye, and fewer social limitati ons related to their 
facial functi on were observed.
In Chapter seven we hypothesized that postoperati ve facial nerve functi on 
should be signifi cantly bett er when tumor is deliberately left  behind during VS 
surgery. Second, we aimed to objecti vely assess the extent of the removal using 
gadolinium-enhanced MRI scans and compared results with the extent of the 
removal as intraoperati vely esti mated by the surgeon. A total of 51 pati ents with 
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large VS were operated using the TL approach. The extent of the resecti on was 
intraoperati vely esti mated as complete, near, and subtotal. The amount of residual 
tumor was measured, and the shape and localizati on was scored on gadolinium-
enhanced magneti c resonance imaging (MRI). Potenti al growth of residual tumor 
was documented with frequent MRI follow-up. Postoperati ve facial nerve functi on 
was classifi ed according to the House-Brackmann classifi cati on. Tumor control with 
good facial nerve functi on could be obtained in most pati ents. A trend was observed 
that facial nerve outcome was more favorable when residual tumor was left  behind. 
Intraoperati ve assessment did not correlate with the amount of residual tumor on 
postoperati ve MRI. Objecti ve documentati on with postoperati ve contrast-enhanced 
MRI to measure the extent of removal is always recommended.
Chapter eight comprises the main conclusions and general discussion of the results 
described in this thesis. Furthermore, clinical implicati ons and future directi ons of 
research are discussed.
Finally, with regard to the aims of the study, we may conclude that more insight was 
provided into pati ents’ percepti ons and outcomes in the treatment of VS. Previous 
knowledge on QoL outcome in the treatment of VS pati ents was confi rmed and new 
informati on such as illness percepti ons and coping behaviour was added. In general, 
pati ents with VS suﬀ er from an impaired QoL and treatment will not necessarily 
restore the pati ent’s quality of daily life. At present, the choice of treatment in VS is 
sti ll a matt er of debate and probably will remain so for a number of reasons. One of 
the principal precepts of medicine “primum non nocere”, fi rst do no harm, should be 
kept in mind by both clinicians and pati ents when discussing the treatment opti ons 
of VS. The major results of this study can make a valuable contributi on to clinical 
decision making and further opti mize management of VS. With awareness regarding 
this topic, we can help to further elucidate QoL percepti on and try to improve QoL in 
VS pati ents in the future.

Samenvatti  ng
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Vesti bularis schwannomen zijn goedaardige hersentumoren die meestal uitgaan 
van de Schwann cellen van de nervus vesti bularis superior. De meest voorkomende 
symptomen van het vesti bularis schwannoom (VS) zijn eenzijdig percepti ef 
gehoorverlies, ti nnitus en/of evenwichtsklachten. Gedurende vele jaren is 
microchirurgische behandeling van de tumor beschouwd als gouden standaard 
in de behandeling van het VS. Er is echter ook een aantal nieuwere, alternati eve 
behandelopti es voor het VS zoals wait and scan of radiochirurgie. Nieuwe 
ontwikkelingen op het gebied van de MRI zorgen ervoor dat de diagnose steeds sneller 
gesteld kan worden en tumorprogressie beter kan worden vastgelegd. Hierdoor 
is er een toenemend aantal VS pati ënten met kleinere en vaak asymptomati sche 
tumoren. Dankzij deze vooruitgang bestaat de behandeling van het VS vaak niet 
meer uit een levensreddende operati e, maar meer uit een profylacti sch beleid voor 
toekomsti ge morbiditeit. De keuze van behandeling blijft  echter onderwerp van 
discussie met voor- en tegenstanders van elke modaliteit. Het is gebruikelijk dat 
in de evaluati e van de behandeling van een VS, de primaire uitkomstmaten zoals 
mortaliteit of morbiditeit worden gebruikt. Het onderwerp kwaliteit van leven (KvL) 
speelt echter een steeds grotere rol in de evaluati e van de behandeling. Het blijkt dat 
KvL clinici informati e kan geven die niet alti jd met de gebruikelijke uitkomstmaten 
kan worden bepaald. Dit proefschrift  beschrijft  KvL tezamen met enkele belangrijke 
klinische aspecten in pati ënten met een VS op het moment van de diagnose en na 
behandeling met wait and scan, micro- of radiochirurgie.
In hoofdstuk 1 wordt een algemene introducti e gegeven met een kort overzicht 
van de verschillende behandelopti es waarna de percepti es van de pati ënt en uitkomst 
van behandeling van het VS aan bod komen. Aan het eind van dit hoofdstuk wordt 
het doel van de studie behandeld.
Hoofdstuk 2 behandelt de KvL, ziektepercepti es en het copinggedrag van 
pati ënten met een VS op het moment van de diagnose. De ziektecogniti es en het 
coping gedrag worden gemeten met twee vragenlijsten: de Illness Percepti on 
Questi onnaire (IPQ-R) en de Utrechtse Coping Lijst (UCL). De algemene KvL werd 
gemeten met behulp van de gevalideerde SF-36. In een prospecti eve analyse van 79 
pati ënten met een klein tot middelgroot VS, werd aangetoond dat ziektecogniti es, 
coping en met name KvL in pati ënten met een VS duidelijk verminderd waren in 
vergelijking met de referenti ewaarden. Onbehandelde pati ënten met VS hadden 
ook verminderde acti eve en passieve coping mechanismen en zochten minder 
sociaal contact in vergelijking met andere pati ënten. De resultaten van deze studie 
Samenvatti  ng | 139 
tonen aan dat pati ënten met een VS vanaf het begin van de diagnose lijden onder 
hun ziekte. Deze bevindingen kunnen van invloed zijn op de beslisvorming en op 
het opti maliseren van contact met pati ënten. Verder zou het veranderen van de 
ziektecogniti es en het copinggedrag door middel van een interventi e de KvL in deze 
pati ënten kunnen verbeteren. 
Hoofdstuk 3 beschrijft  het natuurlijk beloop van de tumor met begeleidende 
symptomen en de ontwikkeling van de KvL gedurende follow-up in een wait and scan 
populati e. Een groep van 70 pati ënten werd initi ëel geïncludeerd in het wait and 
scan - protocol en vervolgd gedurende gemiddeld 43 maanden. Tijdens de inclusie 
in het protocol hadden alle pati ënten een kleine tot middelgrote tumor. De KvL 
werd met behulp van de SF-36 gemeten aan het begin van de observati eperiode en 
aan het eind in de pati ënten die nog steeds geïncludeerd waren. De bestudeerde 
pati ënten hadden allemaal kleine, niet groeiende tumoren met relati ef weinig 
progressie van symptomen gedurende de periode. Uit onze resultaten blijkt dat 
conservati eve behandeling van deze pati ënten de KvL niet signifi cant beïnvloedde. 
In de meeste tumoren was er geen sprake van progressie en het bruikbaar gehoor 
werd gespaard in meer dan de helft  van de pati ënten met een bruikbaar gehoor. Een 
initi ële afwachtende behandeling is daarom een veilige behandeling voor pati ënten 
met kleinere tumoren. Verder werd er geen signifi cante relati e gevonden tussen 
begeleidende symptomen en KvL. Tijdens follow-up werd wel progressie van het 
gehoorverlies gemeten. Pati ënten moeten hierover worden ingelicht voorafgaande 
aan de behandeling.
Hoofdstuk 4 behandelt een retrospecti eve studie over KvL en enkele belangrijke 
klinische aspecten van radiochirurgie uitgevoerd met de lineaire accelerator. In totaal 
werden 72 nieuwe VS pati ënten met een unilateraal VS behandeld met lineaire 
accelerator radiochirurgie met marginale dosis van 12 Gy. Uiteindelijk werd de SF-
36 door 64 pati ënten ingevuld en de scores vergeleken met de referenti e populati e. 
Lokale tumor controle en symptomen werden ook bestudeerd. De resultaten lieten 
zien dat er een goede tumor controle en weinig morbiditeit is na een follow-up 
van 34 maanden na behandeling. Weinig pati ënten rapporteerden een toename 
van symptomen, waarbij geen signifi cante relati e werd gevonden met de KvL. Na 
radiochirurgische behandeling waren de KvL scores iets lager dan de scores van de 
normpopulati e. Er kan worden geconcludeerd dat pati ënten na radiochirurgie een 
verminderde KvL hebben ten opzichte van een normaal populati e. Radiochirurgie 
biedt goede klinische uitkomst, welke vergelijkbaar is met andere studies. Deze studie 
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is een van de weinige studies die over KvL rapporteert na low dose radiochirurgie. 
Het resultaat van deze studie is dan ook van belang bij het informeren van pati ënten 
met kleinere of middelgrote tumoren, waarvoor radiochirurgie steeds vaker de keuze 
van behandeling wordt. 
Hoofdstuk 5 richt zich op het eﬀ ect van translabyrinthaire (TL) brughoekchirurgie 
op de KvL in pati ënten met een VS en invaliderende duizeligheidsklachten. In totaal 
werden 18 pati ënten met een unilateraal intracanaliculair VS met onbruikbaar 
gehoor aan de tumor zijde en invaliderende aanvalsgewijze duizeligheid prospecti ef 
bestudeerd. Na initi eel conservati ef behandeld te zijn met uitgebreide vesti bulaire 
oefentherapie, werden pati ënten uiteindelijk geopereerd via de TL benadering omdat 
de invaliderende duizeligheid persisteerde. De preoperati eve en postoperati eve KvL 
werd gemeten met behulp van de SF-36 en DHI. De preoperati eve KvL was verminderd 
door de invaliderende duizeligheidsklachten, maar verbeterde sterk na TL operati e. 
Maar de KvL was na operati e nog steeds minder dan de KvL van onze referenti e 
populati e. Tot nu toe is er weinig ander bewijs over alternati eve behandelingen zoals 
een chemische labyrintectomie of radiochirurgische behandeling. Uit de resultaten 
van deze studie blijkt dat microchirurgische behandeling via de TL approach, een 
duidelijke verbetering geeft  van de KvL in deze pati ënten. Microchirurgische 
behandeling moet worden overwogen in pati ënten met kleine en middelgrote 
tumoren met blijvende invaliderende duizeligheid. 
In hoofdstuk 6 wordt een nieuwe methode van de facialis-hypoglossus coaptati e 
(FHT) beschreven om aangezichtsverlamming na (chirurgisch) trauma te verhelpen. 
Met behulp van deze techniek wordt de nervus facialis vrijgelegd uit het mastoid 
over een traject van 1,5 tot 2 cm om zo een directe coaptati e te maken met een 
deel van de nervus hypoglossus. Deze techniek vermijdt het gebruik van een graft  
en is daarom een veilige techniek omdat er in principe maar één coaptati e plaats is. 
Hierdoor wordt het risico op falen van de reconstructi e door dehiscenti e verminderd. 
Een ander voordeel in vergelijking met andere FHT is dat de nervus hypoglossus maar 
gedeeltelijk wordt geïncideerd waardoor de het risico op halfzijdige verlamming 
of atrofi e van de tong verminderd is. De functi e van de nervus facialis wordt niet 
alleen gescoord met behulp van de House-Brackmann classifi cati e, welke veel 
gebruikt wordt door chirurgen, maar ook via de Facial Disability Index (FDI). Deze 
questi onnaire is gerelateerd aan de functi e van de nervus facialis. In bijna alle 
pati ënten, hebben we de doelen van dynamische facialis reconstructi e bereikt: 
een functi onerende mondmusculatuur en voldoende sluiti ng van het oog om oog 
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problemen te voorkomen. Ook de tongfuncti e werd gespaard in alle pati ënten en 
er was geen atrofi e van de tong. De klinische en KvL uitkomsten van onze techniek 
kwamen overeen met andere resultaten. Er werden functi onele verbeteringen bij 
eten, drinken en het sluiten van het oog gerapporteerd en minder sociale beperkingen 
als gevolg van de nervus facialis functi e.
In hoofdstuk 7 stelden we dat de postoperati eve nervus facialis functi e beter zou 
moeten zijn als residu tumor wordt achtergelaten op de nervus facialis ti jdens de 
operati e. Ook was het doel om de mate van resecti e objecti ef te bepalen met behulp 
van een MRI met gadolinium als contrastmiddel waarbij de resultaten dan vergeleken 
werden met de peroperati ef ingeschatt e mate van resecti e door de chirurg. In totaal 
werden 51 pati ënten met grote tumoren geopereerd via de TL benadering. De mate 
van resecti e werd intraoperati ef ingeschat als compleet, ‘near’ en subtotaal. De 
hoeveelheid residu tumor werd gemeten en de omvang en lokalisati e werd gescoord 
op de MRI met contrast. Eventuele uitgroei van residu werd gedocumenteerd 
door herhaalde MRIs ti jdens follow-up. Postoperati eve nervus facialis functi e werd 
geclassifi ceerd volgens de House-Brackmann classifi cati e. Een goede tumor controle 
en nervus facialis functi e werd bereikt in het merendeel van de pati ënten. Er werd 
een trend gezien dat de nervus facialis uitkomst verbeterde in geval van residu tumor. 
De intraoperati eve inschatti  ng kwam niet overeen met de hoeveelheid residu op de 
postoperati eve MRI. Objecti eve documentati e van de mate van resecti e met behulp 
van MRI met contrast wordt alti jd aangeraden. 
Hoofdstuk 8 bevat de belangrijkste conclusies en de discussie van de resultaten 
in dit proefschrift . Verder worden een aantal belangrijke implicati es voor de klinische 
prakti jk en voor vervolgonderzoek gegeven. 
Gezien de resultaten van het in dit proefschrift  beschreven onderzoek kan worden 
geconcludeerd dat er meer inzicht is verkregen in de percepti e van de pati ënt over de 
aandoening en ten aanzien van uitkomsten van behandeling van het VS. De eerder 
opgedane kennis van KvL in de behandeling van het VS kon worden bevesti gd en 
nieuwe informati e zoals over ziektecogniti es en coping gedrag werd toegevoegd 
aan bestaande literatuur. Het blijkt dat pati ënten met een VS over het algemeen 
een verminderde KvL ervaren en dat behandeling niet hoeft  te leiden tot een herstel 
van KvL. Op dit moment is de keuze van behandeling nog steeds onderwerp van 
discussie wat waarschijnlijk ook nog zo zal blijven door verschillende redenen. Een 
van de belangrijkste stelregels in de geneeskunde ‘primum non nocere’, oft ewel in 
ieder geval geen kwaad doen, moet in gedachte worden gehouden door zowel clinici 
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als pati ënten wanneer de behandelingsopti es voor het VS worden besproken. De 
belangrijkste resultaten van deze studie kunnen een waardevolle aanvulling zijn voor 
de klinische besluitvorming en het opti maliseren van het overleg met de pati ënt met 
een VS. Een beter besef van het onderwerp kan helpen de percepti e van de KvL in 
pati ënten met een VS te verklaren en mogelijk in de toekomst ook te verbeteren.
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